<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Ophthalmol</journal-id><journal-id journal-id-type="publisher-id">Indian Journal of Ophthalmology</journal-id><journal-title-group><journal-title>Indian Journal of Ophthalmology</journal-title></journal-title-group><issn pub-type="ppub">0301-4738</issn><issn pub-type="epub">1998-3689</issn><publisher><publisher-name>Medknow Publications</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">18711264</article-id><article-id pub-id-type="pmc">2636142</article-id><article-id pub-id-type="publisher-id">IndianJOphthalmol_2008_56_5_363_42412</article-id><article-categories><subj-group subj-group-type="heading"><subject>Symposium</subject></subj-group></article-categories><title-group><article-title>Anterior segment manifestations of human immunodeficiency virus/acquiredimmune deficiency syndrome</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Biswas</surname><given-names>Jyotirmay</given-names></name><degrees>MS</degrees></contrib><contrib contrib-type="author"><name><surname>Sudharshan</surname><given-names>S</given-names></name><degrees>DO</degrees></contrib></contrib-group><aff>Sankara Nethralaya, 18, College Road, Chennai - 600 006, India</aff><author-notes><corresp id="cor1">Correspondence to Dr. Jyotirmay Biswas, Medical and Vision ResearchFoundations, Sankara Nethralaya, 18, College Road, Chennai - 600 006,Tamil Nadu, India. Email: <email>drjb@sankaranethralaya.org</email></corresp></author-notes><pub-date pub-type="ppub"><season>Sep-Oct</season><year>2008</year></pub-date><volume>56</volume><issue>5</issue><fpage>363</fpage><lpage>375</lpage><history><date date-type="received"><day>28</day><month>4</month><year>2007</year></date><date date-type="accepted"><day>22</day><month>2</month><year>2008</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Indian Journal of Ophthalmology</copyright-statement><copyright-year>2008</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-ShareAlike 3.0 Unported,  which permits unrestricted use, distribution, and reproduction in any medium, provided the originalwork is properly cited.</license-p></license></permissions><abstract><p>Ocular complications are known to occur as a result of human immunodeficiency virus (HIV) disease. Theycan be severe leading to ocular morbidity and visual handicap. Cytomegalovirus (CMV) retinitis is thecommonest ocular opportunistic infection seen in acquired immune deficiency syndrome (AIDS). Thoughposterior segment lesions can be more vision-threatening, there are varied anterior segment manifestationswhich can also lead to ocular morbidity and more so can affect the quality of life of a HIV-positive person.Effective antiretroviral therapy and improved prophylaxis and treatment of opportunistic infections have ledto an increase in the survival of an individual afflicted with AIDS. This in turn has led to an increase in theprevalence of anterior segment and adnexal disorders. Common lesions include relatively benign conditionssuch as blepharitis and dry eye, to infections such as herpes zoster ophthalmicus and molluscum contagiosumand malignancies such as squamous cell carcinoma and Kaposi&#x02032;s sarcoma. With the advent of highly activeantiretroviral therapy, a new phenomenon known as immune recovery uveitis which presents with increasedinflammation, has been noted to be on the rise. Several drugs used in the management of AIDS such asnevirapine or indinavir can themselves lead to severe inflammation in the anterior segment and adnexa of theeye. This article is a comprehensive update of the important anterior segment and adnexal manifestations inHIV-positive patients with special reference to their prevalence in the Indian population.</p></abstract><kwd-group><kwd>Acquired immune deficiency syndrome</kwd><kwd>anterior segment lesions</kwd><kwd>highly active antiretroviral therapy</kwd><kwd>herpes zoster ophthalmicus</kwd><kwd>human immunodeficiency virus</kwd><kwd>immune recovery uveitis</kwd><kwd>Kaposi&#x02032;s sarcoma</kwd><kwd>molluscum contagiosum</kwd></kwd-group></article-meta></front><body><p>			Ocular complications are common in human immunod-			eficiency virus (HIV)-infected individuals with at least 50&#x02013;75%			of infected individuals expected to develop ocular disease			at some point of time during the course of the disease in			the pre- highly active antiretroviral therapy (HAART) era.<xref ref-type="bibr" rid="ref1">1</xref>,<xref ref-type="bibr" rid="ref2">2</xref> Opportunistic infections develop when there is a deterioration			of the immune status of the individual which can be measured			with the help of CD4 cell counts. Posterior segment lesions,			especially cytomegalovirus (CMV) retinitis, are associated			with severe visual morbidity. Corneal and anterior segment			lesions affect more than 50% of all HIV patients. Ocular adnexal			complications, seen in about 25% of patients, can be a sign of			severe systemic immunosuppression.<xref ref-type="bibr" rid="ref3">3</xref> Introduction of HAART			has dramatically changed the scenario of the acquired immune			deficiency syndrome (AIDS) epidemic. One of the hallmarks			of progressive immune deficiency is a steady decline in the			absolute number of CD4+ T-lymphocytes.<xref ref-type="bibr" rid="ref4">4</xref> Treatment of HIV			infection with these regimens seeks to inhibit progression			to AIDS (defined by a CD4 cell count of &#x0003c;200 cells/mm<sup>3</sup>) or			death. This is by reducing plasma HIV RNA to permanently			low levels, reduction in the viral load and a rise in CD4 cell			counts which helps in improvement in the immune status of the			individual.<xref ref-type="bibr" rid="ref5">5</xref> With the advent of HAART, HIV and AIDS-related			morbidity and mortality have drastically decreased in the			developed world.<xref ref-type="bibr" rid="ref6">6</xref>-<xref ref-type="bibr" rid="ref8">8</xref> Patients on HAART are less likely			to be affected by blinding posterior segment infections and there			has been a marked reduction even in the occurrence of anterior			segment and adnexal lesions. Though not all anterior segment			diseases are vision-threatening, they can modify quality of			life of patients and do require immediate ophthalmic care.<xref ref-type="bibr" rid="ref9">9</xref>			More than 90% of HIV-infected individuals live in developing			nations. In developing regions like India and the African			continent there has been an explosive increase in the number of			people with HIV disease, contributing to more than two-thirds			of the world&#x02032;s population of HIV-infected individuals. It is			compounded by the fact that in these areas, patients have little			or no access to HAART. As of December 2005, it was estimated			that 40.3 million people worldwide were infected with HIV.			In addition, there were 4.9 million newly diagnosed cases in			2005.<xref ref-type="bibr" rid="ref10">10</xref> For many poor countries, there may be no greater or			more immediate threat to public health and economic growth			than HIV.<xref ref-type="bibr" rid="ref11">11</xref> In African populations, anterior segment and			external ocular diseases, such as squamous cell carcinoma,			seem to predominate among ophthalmic problems.<xref ref-type="bibr" rid="ref9">9</xref>			</p><p>			HAART-led immune recovery acts like a double-edged			sword. Clinical immune recovery is, in general, of great benefit to			the patient. But 10&#x02013;25% of people initiated on HAART, experience			&#x02033;immune recovery&#x02033; or immune reconstitution inflammatory			problems, the majority of which are dermatologic.<xref ref-type="bibr" rid="ref12">12</xref> Immune			recovery or immune reconstitution inflammatory syndrome			(IRIS) refers to the acute immune-mediated inflammatory			response to dormant antigens that occurs when CD4 cell counts			rise after treatment with HAART.<xref ref-type="bibr" rid="ref13">13</xref>-<xref ref-type="bibr" rid="ref15">15</xref>			</p><p>			HAART-mediated improvement of immune function in			patients with AIDS may also alter the way the eye responds			to both opportunistic infections, especially CMV and to			treatment, resulting in changes in the clinical manifestations			of the ocular lesions. There have been newer ocular diseases;			both in the anterior and posterior segments, in these patients			on HAART.<xref ref-type="bibr" rid="ref7">7</xref> Few of the drugs used in the management of			opportunistic infections in AIDS can also cause anterior			segment manifestations. The purpose of this article is to			provide a comprehensive update of the important anterior			segment and adnexal manifestations in HIV-positive patients			with special reference to their prevalence in the Indian			population.			</p><p>Anterior segment manifestations in an HIV-infected			individual can be grouped into those caused due to the disease			itself and those related to its management.			</p><p>				<list list-type="alpha-upper"><list-item><p>Anterior segment lesions due to HIV</p><p>							<list list-type="order"><list-item><p>Infections</p><p>									<list list-type="alpha-lower"><list-item><p>Viral</p></list-item><list-item><p>Bacterial</p></list-item><list-item><p>Fungal</p></list-item><list-item><p>Protozoal</p></list-item><list-item><p>Others</p></list-item></list>								</p></list-item><list-item><p>Neoplasia</p></list-item><list-item><p>Others</p></list-item></list>						</p></list-item><list-item><p>Iatrogenic/post-treatment manifestations</p><p>						<list list-type="order"><list-item><p>Immune recovery uveitis</p></list-item><list-item><p>Drug-induced uveitis</p></list-item></list>					</p></list-item></list>			</p><sec sec-type=""><title>Anterior segment lesions due to HIV disease</title><sec><title>Infections</title><sec><title>Viral diseases</title><p>						Herpes zoster ophthalmicus<xref ref-type="bibr" rid="ref4">4</xref>,<xref ref-type="bibr" rid="ref5">5</xref>						</p><p>						Herpes zoster ophthalmicus (HZO) is caused by varicella <italic> zoster</italic>						virus (VZV) which causes varicella (chicken pox) and herpes						zoster (shingles). Over 90% of the population develops clinical						or serologic evidence of infection with VZV by adolescence,						and the prevalence is almost 100% by age 60 years.<xref ref-type="bibr" rid="ref9">9</xref>,<xref ref-type="bibr" rid="ref16">16</xref>						</p><p>						The virus usually remains latent in sensory neurons. In						immunocompetent individuals, latent VZV has been detected in						65-90% of trigeminal, 50-80% of thoracic, and 70% of geniculate						ganglia.<xref ref-type="bibr" rid="ref9">9</xref> It can reactivate in response to local surgery/trauma or						in the setting of depressed cell-mediated immunity (associated						with aging, malignancies such as Hodgkin&#x02032;s disease/leukemia						or immunosuppressive treatment).						</p><p>						Herpes zoster eventually occurs in 10-20% of all individuals						and reactivation in the ophthalmic division of the trigeminal						nerve gives rise to HZO.<xref ref-type="bibr" rid="ref9">9</xref>						</p><p>						It is characterized by vesiculobullous rash over the						distribution of the ophthalmic branch of the trigeminal nerve						[<xref ref-type="fig" rid="F1">Figure 1</xref>] and may be associated with dendritiform and stromal						keratitis, conjunctivitis, blepharitis, uveitis (with secondary						glaucoma), hemorrhagic hypopyon,<xref ref-type="bibr" rid="ref17">17</xref> scleritis, retinitis<xref ref-type="bibr" rid="ref18">18</xref> or encephalitis. Tissue damage can be mediated through a						necrotizing vasculitis.						</p><p>						Incidence of HZO is greater in HIV-infected individuals						than in non-infected, age-adjusted populations. Approximately						5&#x02013;15% of HIV-positive patients are co-infected with herpes						zoster, but only half of these individuals are at risk of ocular						involvement.<xref ref-type="bibr" rid="ref3">3</xref> It can even be an initial manifestation of HIV.						Hodge and associates found that HIV-infected individuals had						a relative incident risk ratio for HZO of 6.6:1, when compared						to individuals who are HIV-negative.<xref ref-type="bibr" rid="ref1">1</xref>						</p><p>						In immunosuppressed individuals, herpes zoster is more						likely to be severe, prolonged, and can lead to viremia, which						may result in visceral or neurologic infection, leading to						increased morbidity and mortality.<xref ref-type="bibr" rid="ref9">9</xref> Herpes zoster presenting						in any apparently healthy young individual (&#x0003c;45 years)						with these characteristics and without any obvious cause of						immunosuppression should be investigated for HIV. Diagnosis						of HZO is mainly clinical. To confirm a clinical diagnosis,						however, various tests are available, including virus cultures,						Tzanck smears, polymerase chain reaction (PCR) techniques for						VZV DNA, fluorescent antibody testing, and antigen detection						by direct immunofluoresence.<xref ref-type="bibr" rid="ref19">19</xref>						</p><p>						In immunocompetent hosts, the virus has not been						recovered by culture beyond the first 48 h of the disease. VZV						DNA has been detected on the ocular surface for as long as						34 days after the onset of rash and in excised corneal buttons						obtained during penetrating keratoplasty up to eight years						after active disease.<xref ref-type="bibr" rid="ref20">20</xref>						</p><p>						Treatment of HZO in individuals with HIV disease						requires aggressive initial treatment, with intravenous						acyclovir, followed by a prolonged course of oral antivirals as						&#x02033;maintenance therapy,&#x02033; to prevent recurrence.<xref ref-type="bibr" rid="ref9">9</xref> The regime is						intravenous acyclovir (10 mg/kg of body weight eight-hourly						for seven days followed by an oral maintenance regimen of						800 mg five times a day for at least three to six weeks). Early						initiation of systemic anti-viral therapy can reduce the duration						of skin lesions and ocular complications by about 50%.<xref ref-type="bibr" rid="ref9">9</xref>,<xref ref-type="bibr" rid="ref21">21</xref> The most appropriate duration of treatment for HZO has not been						determined for the general population, although virus has						been recovered from skin lesions up to 14 days into the course						of infection. In resistant cases, famciclovir can be used three						times daily in 500 mg dosages as well. In cases of resistance						to thymidine kinase-dependent acyclovir or famciclovir, IV						foscarnet may be used.<xref ref-type="bibr" rid="ref22">22</xref>						</p><p>						A recent study<xref ref-type="bibr" rid="ref18">18</xref> showed infection with Herpes zoster to						be severe, of long duration with higher rate of complications,						increased need for hospitalization and higher rates of recurrent						herpes zoster in group patients. Though post-herpetic neuralgia						is a very frequent complication for both groups (HIV-positive						and HIV-negative) its duration is longer in HIV/AIDS						patients in comparison to HIV-negative group. There was no						significant difference in the severity, duration or complications						of the disease among male and female patients. HIV-infected						individuals with HZO should have regular fundus evaluation						until complete resolution of skin vesicles to watch for retinal						infection.<xref ref-type="bibr" rid="ref19">19</xref>						</p><p>						In a series of young individuals with HZO, those with						risk factors for HIV infection had a higher rate of ocular						complications (57%) than those without risk factors (38%).<xref ref-type="bibr" rid="ref23">23</xref>						</p><p>						There has also been a reported increase in the incidence of						herpes <italic>zoster</italic> in patients with AIDS immediately after therapy						with protease inhibitors. Martinez <italic>et al</italic>.,<xref ref-type="bibr" rid="ref24">24</xref> found that within						a median follow-up of 64 weeks (range, 34 to 103 weeks),						14 patients (7%) had a first episode or a recurrence of herpes						zoster (6.2 episodes per 100 patient-years). No episodes of zoster						were diagnosed before Week 4. They noted that the risk of zoster						was independent of age, sex, type of protease inhibitor and						CD4 +  counts and viral load at baseline and Month 1. But an						increase in CD8 +  lymphocyte proportion at Month 1 of &#x0003e; 5%						(HR 32; 95% CI 8.1 to 126.4) was independently associated with						the risk of herpes zoster. This will help identifying persons at risk						and prophylactic antiviral therapy can be instituted in them.						</p><p>						In our series of 120 patients on HAART seen between 2002						and 2005, seven patients had HZO and in five of these patients						the CD4 counts were more than 200 cells/cu mm (unpublished						data) and in two of these patients, the counts were between 150						to 200 cells/cu mm. HZO seems to occur in patients on HAART						with improvement in their immune status. In a previous study						from our institute in the pre-HAART era, there was only one						patient with HZO out of a series of 100 patients.<xref ref-type="bibr" rid="ref25">25</xref>						</p><p>						Some patients develop severe and debilitating post-herpetic						neuralgia after resolution of the oculocutaneous lesions. Post-						herpetic neuralgia can be treated with analgesics and anti-						inflammatory drugs such as topical lidocaine cream (5%).<xref ref-type="bibr" rid="ref26">26</xref>						Acyclovir therapy, initiated within 72 h of onset of skin rash,						also reduces the risk of post-herpetic neuralgia.<xref ref-type="bibr" rid="ref27">27</xref> Pain relief						in severe cases may be obtained with amitryptiline (25 mg to						150 mg orally daily in slowly increasing dose). Opioids have						been found to be more potent and better tolerated than tricyclic						antidepressants.<xref ref-type="bibr" rid="ref28">28</xref> Currently, gabapentin, up to 3,600 mg per day						in three divided doses, has emerged as a first-line treatment for						post-herpetic neuralgia and is found to be effective for treatment						of pain and sleep interference associated with this condition.<xref ref-type="bibr" rid="ref29">29</xref>						</p></sec><sec><title>Viral keratitis</title><p>						VZV and herpes simplex virus (HSV) are the most common						etiologic agents of infectious keratitis.<xref ref-type="bibr" rid="ref3">3</xref> Although ocular						infection is usually known to occur with HSV-1, documented						cases of HSV&#x02013;2 ocular infection have also been reported,						including an individual with AIDS who was found to have						simultaneous HSV-1 and -2 infection of the cornea.<xref ref-type="bibr" rid="ref30">30</xref>					</p><p>					Herpetic keratitis can cause painful and often recurrent					corneal ulcerations with a characteristic branching or dendritic					pattern on slit-lamp examination. Epithelial keratitis typically					appears in conjunction with follicular conjunctivitis and					vesicular eyelid lesions; stromal and interstitial keratitis present					less frequently. HSV keratitis is usually associated with corneal					scarring, iritis and raised intraocular pressure and is known					to recur frequently.					</p><p>					VZV keratitis may be accompanied by herpes zoster					ophthalmicus in 65% of individuals with HZO, dendritiform					lesions occur in up to 51% cases.<xref ref-type="bibr" rid="ref9">9</xref> Among those with corneal					involvement, neurotrophic keratitis occurs in 25% and rarely,					superadded bacterial infection can occur. Both epithelial and					stromal disease has been described in the absence of skin					lesions, a condition named as herpetic zoster sine herpete.<xref ref-type="bibr" rid="ref31">31</xref>,<xref ref-type="bibr" rid="ref32">32</xref>					</p><p>					HIV-infected patients with HZO are more likely to					experience corneal involvement than their non-infected					counterparts (89% vs. 65%), and corneal perforation also					has an increased incidence according to one report.<xref ref-type="bibr" rid="ref3">3</xref>					Individuals with AIDS can develop a chronic VZV infection					of the corneal epithelium. Engstrom and Holland<xref ref-type="bibr" rid="ref33">33</xref> were the					first to describe such a case; their patient had been treated					presumptively. Lesions of chronic VZV epithelial keratitis					in HIV-infected individuals can be pleomorphic, often					with multiple components and associated with thickened					opaque epithelium. They tend to be more delicate and lacy					in appearance than the discrete dendrites of HSV epithelial					keratitis or the classic, broad, plaque-like VZV dendrites					that have been described at the onset of HZO. Peripheral					ulcerative keratitis can occur in HIV-infected patients with					HZO,<xref ref-type="bibr" rid="ref9">9</xref> as described previously in individuals with debilitating					systemic disorders.					</p><p>					Corneal stromal involvement has been reported infrequently					in individuals with AIDS or other immunosuppressed states.					It is thus possible that the T-lymphocyte dysfunction in HIV-					infected individuals may actually protect them from developing					HSV stromal disease.<xref ref-type="bibr" rid="ref9">9</xref> Punctate corneal dendritic lesions					described in HIV-positive hosts do not seem to differ from					those seen in immunocompetent hosts except that they may					be larger and more peripherally located. The pathognomonic					bulb-tipped branching pattern seen on slit-lamp examination,					however, remains the same in both groups and helps confirm					the clinical diagnosis.					</p><p>					In a series of six patients with AIDS and HSV keratitis,					Young and associates<xref ref-type="bibr" rid="ref34">34</xref> emphasized atypical clinical features of					the disease, including a predilection for marginal, as opposed					to central epithelial keratitis, a relative resistance to treatment					(mean healing time of three weeks compared to the two weeks					typical for immunocompetent individuals); and more frequent					and lengthier recurrences. Similar observations were made in a					retrospective cohort study<xref ref-type="bibr" rid="ref35">35</xref> which compared the incidence and					clinical course of HSV keratitis over a 11&#x02013;year period among					1,800 patient visits of individuals who were HIV-infected and					48,200 patient visits of individuals who were not HIV-infected,					and it found no difference between the groups with regard					to incidence of HSV keratitis, lesion type (epithelial versus					stromal), lesion location (central versus peripheral), and					treatment time. The recurrence rate, however, was 2.48 times					more frequent in HIV-infected individuals.					</p><p>					More recently, a 2003 study from Nigeria found that half					of 10 healthy-appearing individuals with HZO were found					to be infected with HIV.<xref ref-type="bibr" rid="ref36">36</xref> Confirmed HIV seropositivity was					16.7% in recurrent HSK cases as against 3.3% in the matched					first-episode HSK cases in an Indian study.<xref ref-type="bibr" rid="ref37">37</xref>					</p><p>					Overall recurrence rates were significantly higher amongst					the HIV-positive group even among other studies. After the first					episode a site of chronic latent infection is established in the					cornea and immunosuppression as a result of HIV infection					probably may impair those mechanisms which are normally					responsible for containing such an infection in the cornea.<xref ref-type="bibr" rid="ref38">38</xref>					</p><p>					Diagnosis of HSV infection is primarily clinical, but					laboratory studies, including viral culture, direct fluorescent					antibody tests for HSV antigens and PCR techniques for					HSV DNA can help to confirm the diagnosis, especially in					cases of diagnostic dilemma.<xref ref-type="bibr" rid="ref9">9</xref> Treatment is commonly with					topical agents such as acyclovir eye ointment five times daily					or vidarabine ointment 3% five times daily and cycloplegics.					Debridement of the ulcer using a cotton-tip applicator may					increase the healing rate.					</p><p>					According to Herpetic Eye Disease Study group<xref ref-type="bibr" rid="ref39">39</xref> long-term					suppressive oral acyclovir therapy (400 mg twice daily for one					year) reduces the rate of recurrent HSV epithelial keratitis					and stromal keratitis. The benefit of acyclovir is greatest for					patients who have experienced prior HSV stromal keratitis.					Long-term suppressive oral acyclovir therapy may also benefit					HIV-infected individuals with a history of HSV eye disease, in					light of the increased recurrence rate of HSV keratitis in this					population.<xref ref-type="bibr" rid="ref9">9</xref>					</p><p>					In resistant strains, famciclovir 125 to 500 mg three times					daily or foscarnet can be substituted instead of acyclovir.					Bodaghi <italic>et al</italic>.,<xref ref-type="bibr" rid="ref40">40</xref> described a case of a young HIV-positive					female with chronic keratitis not responding to acyclovir.					Conventional virological methods remained inconclusive					and <italic>in situ</italic> hybridization and polymerase chain reaction					(PCR) rapidly confirmed the diagnosis of HSV-1 keratitis. The					thymidine kinase gene sequence revealed the presence of five					variations and they postulated that this gene may be associated					with acyclovir resistance.					</p><p>					Interferon has also been used for the treatment and					prevention of HSV epithelial keratitis. Patients with a history					of HZO on a HAART regimen may be susceptible to immune					recovery. In VZV-mediated stromal keratitis, as reported by					Naseri and Margolis,<xref ref-type="bibr" rid="ref41">41</xref> in a patient with history of resolved					HZO, T cells presumably recognized and responded to residual					VZV antigens in the corneal stroma to cause the keratitis.					HAART (with protease inhibitors) may potentially double the					incidence of herpes zoster and related ocular involvement in					AIDS patients, although treatment with nucleoside analogue					reverse transcriptase inhibitors does not pose the same risk.					Thus, there is an increased risk of recurrence in HIV-infected					individuals and stromal keratitis as part of IRIS.					</p></sec><sec><title>Cytomegalovirus keratitis</title><p>					CMV which can be transmitted by blood, saliva, breast milk,					and mucous membrane contact is usually asymptomatic in					immunocompetent individuals, but can sometimes produce					transient conjunctivitis. CMV retinitis is the commonest AIDS-					related opportunistic infection of the eye, but rarely involves					the anterior segment tissues. CMV infection of the iris has					been reported in a patient with CMV retinitis.<xref ref-type="bibr" rid="ref42">42</xref> CMV has been					reported to be associated with both epithelial and/or stromal					keratitis, although both conditions are probably uncommon.<xref ref-type="bibr" rid="ref9">9</xref>					</p><p>					Corneal endothelial deposits have been described in about					80% of eyes with CMV retinitis.<xref ref-type="bibr" rid="ref43">43</xref> These asymptomatic lesions,					seen in up to 81% of cases of HIV/AIDS-related CMV retinitis					appear as linear or stellate lesions and form a reticular pattern.<xref ref-type="bibr" rid="ref44">44</xref>					Best visualized in retroillumination, they are commonly found					in the inferior cornea. These deposits are known to be composed					of fibrin and macrophages, with no active CMV infection. CMV					has been proven, with the help of aqueous humor analysis to					be the causative agent of endothelitis and anterior uveitis in					immunocompetent patients.<xref ref-type="bibr" rid="ref45">45</xref>,<xref ref-type="bibr" rid="ref46">46</xref>					</p><p>					CMV has been reported to be associated with anterior uveitis					with sectoral iris atrophy<xref ref-type="bibr" rid="ref47">47</xref> and with secondary glaucoma<xref ref-type="bibr" rid="ref48">48</xref> in immunocompetent individuals. Similar cases have not been					found in patients with AIDS.					</p><p>					For immunocompromised patients of any age, restoring					immunity prevents herpes virus disease, as seen in the case of					CMV in AIDS patients on HAART. Specific antiviral therapy					during the initial period after transplantation could prevent					reactivation of HSV or CMV in seropositive recipients.					Prophylaxis with antivirals against CMV and other viruses					prior to clinically detectable lesions, remains controversial and					the relative merits/limitations of each approach may guide the					choice.<xref ref-type="bibr" rid="ref49">49</xref> In addition to HIV/AIDS, current antiviral therapy has					been focusing primarily on herpes viruses, hepatitis viruses					and influenza.<xref ref-type="bibr" rid="ref50">50</xref>					</p></sec><sec><title>Molluscum contagiosum<xref ref-type="bibr" rid="ref6">6</xref></title><p>Molluscum contagiosum, caused by a large DNA pox virus,					affects up to 5% of HIV-infected patients and is highly contagious.					It is transmitted by direct contact and has an incubation period of					six to eight weeks.<xref ref-type="bibr" rid="ref9">9</xref> It is seen in children and young adults.					</p><p>					In immunocompetent children, it is transmitted via fomites,					infected clothing, bed linen, and towels. They are usually fewer					in number, smaller in size and are found to be unilateral. In					young adults, it is typically transmitted sexually. Children					aged 0 to14 years account for 90% of molluscum contagiosum					episodes.<xref ref-type="bibr" rid="ref51">51</xref> In HIV-positive individuals, such lesions can occur					in the eyelid and conjunctiva and are characteristically larger					in number and size, often confluent, bilateral and resistant to					therapy [<xref ref-type="fig" rid="F2">Figure 2</xref>]. Face, trunk and genitalia are commonly					affected. A distribution in the chin-strap region is common					in HIV-positive patients. The lash line should be examined					carefully in all patients with chronic conjunctivitis so as not to					miss a molluscum lesion.					</p><p>					Molluscum contagiosum is believed to be more common					in persons with AIDS due to profound dysfunction of					T-lymphocyte-mediated immune response, associated with					HIV infection. Molluscum contagiosum lesions of the eyelid					have even been reported as the initial clinical manifestation					of HIV disease.<xref ref-type="bibr" rid="ref52">52</xref>,<xref ref-type="bibr" rid="ref53">53</xref> It is characterized by pink or					pearly white wart-like nodules on the skin. Sections of the lesions show large					(20 to 30 microns) eosinophilic hyaline inclusion bodies which					displace the nuclei to the margin. These bodies are composed					of large numbers of virus particles, embedded in a protein					matrix. Rarely, conjunctival involvement in AIDS patients can					also result in nodular pink lesions.<xref ref-type="bibr" rid="ref3">3</xref>					</p><p>					Treatment: Typically these lesions regress on their own in					immunocompetent individuals. Treatment options include					usage of topical agents like phenol and trichloroacetic acid					or serial applications of liquid nitrogen. Incision with or					without curettage, excision, and cryotherapy are equally					effective. Despite treatment, eyelid lesions will commonly					recur in patients with AIDS, usually within six to eight					weeks, corresponding to the incubation period of the virus.					Administration of HAART with restoration of immunity					leads to complete resolution of disseminated molluscum					contagiosum and limitation of infection.					</p><p>					Although HIV-infected individuals suffer from an aggressive					form, severe inflammatory reaction is not known even in					those patients with coexistent conjunctivitis. Paradoxically,					the phenomenon of IRIS after treatment with HAART can					also cause new presentations of molluscum contagiosum in					patients without a history of the disease.<xref ref-type="bibr" rid="ref54">54</xref> Severe conjunctival					inflammation may be noted till regression of lesions. Even					though immune reconstitution does not prevent recurrence of					molluscum contagiosum, newer lesions when they develop are					less severe, as in immunocompetent individuals.<xref ref-type="bibr" rid="ref3">3</xref>					</p></sec></sec><sec><title>Bacterial diseases</title><sec><title>Bacterial keratitis</title><p>Several studies comparing ocular flora in immunocompromised					and immunocompetent individuals have found varied					results.<xref ref-type="bibr" rid="ref9">9</xref> Ocular flora in HIV-infected individuals is not very					different from that in the general population but the risk of					infection with this &#x02033;normal flora&#x02033; may be greater for severely					immunosuppressed individuals.<xref ref-type="bibr" rid="ref3">3</xref>,<xref ref-type="bibr" rid="ref9">9</xref> <italic>Staphylococcus					aureus</italic>, <italic>Staphylococcus epidermidis</italic> and <italic>Pseudomonas aeruginosa</italic> are most					frequently implicated.<xref ref-type="bibr" rid="ref55">55</xref> <italic>Klebsiella oxytoca</italic>, <italic>Streptococcus</italic>,					<italic>Bacillus</italic>, <italic>Micrococcus</italic>, <italic>Capnocytophaga</italic>, and most recently <italic>Acanthameba					species</italic> have also been shown to cause disease, with some					cases of recalcitrant infection requiring keratoplasty and					even evisceration of the globe.<xref ref-type="bibr" rid="ref56">56</xref>-<xref ref-type="bibr" rid="ref58">58</xref> HIV-infected					hosts may be predisposed towards these spontaneous bacterial keratitides					because of preexisting keratoconjunctivitis sicca (KCS) and					viral keratitis, which create corneal epithelial erosions allowing					subsequent bacterial entry. Other risk factors predisposing					to epithelial defects include the use of crack cocaine by HIV-					infected individuals.<xref ref-type="bibr" rid="ref9">9</xref></p><p>The clinical presentation of bacterial keratitis in HIV-infected					individuals differs from that in the general population. In					immunosuppressed individuals, they are usually bilateral,					involve multiple pathogens and carry a higher risk of					perforation. There have been reports of eyes having to be					eventually enucleated despite having been treated with					intensive antibiotic therapy, based on <italic>in vitro</italic> sensitivities, for					more than two weeks.<xref ref-type="bibr" rid="ref59">59</xref></p><p>Paucity of inflammation in immunosuppressed patients also					contributes to delay in diagnosis and treatment. In contrast,					only one eye of the 12 cases of pseudomonal corneoscleritis					in immunocompetent individuals from the same institution					required enucleation.</p><p><italic>Neisseria gonorrhoeae</italic> infection is usually transmitted to the					eye by accidental auto-inoculation and can be unilateral or					bilateral. They cause membranous or pseudomembranous					conjunctivitis with ulceration, scarring and perforation as the					organism can penetrate the normal corneal epithelium. HIV					infection can modify the typical host response to <italic>gonococci</italic>,					resulting in more severe ocular signs and symptoms.<xref ref-type="bibr" rid="ref60">60</xref> Gram					staining and culture helps in the identification of the etiological					agent. Systemic treatment with ceftriaxone or other appropriate					antibiotics must be used to treat <italic>gonococcal</italic> conjunctivitis.					Topical therapy alone will be ineffective.</p></sec></sec><sec><title>Protozoal diseases</title><sec><title>Microsporidial keratitis	<xref ref-type="bibr" rid="ref2">2</xref></title><p><italic>Microsporidia</italic> are spore-forming, obligate intracellular,					protozoan parasites. They are known to cause gastrointestinal					complications such as hepatitis, enteritis and peritonitis in					patients with AIDS. Among the very few reports of human					microsporidiosis reported prior to the AIDS epidemic,<xref ref-type="bibr" rid="ref61">61</xref> three					cases had some form of immunosuppression. They occur when					the CD4 +  counts drop to about 100cells/cu.mm. Thirty-nine					to 44% of HIV-infected individuals with diarrhoea are infected					with <italic>microsporidia</italic>, in comparison to only 2.3% of HIV-infected					individuals without diarrhoea.</p><p>AIDS-associated microsporidial keratoconjunctivitis is					characterized by bilateral superficial punctate epithelial keratitis,					white intraepithelial infiltrates, mild anterior chamber reactions,					and conjunctivitis in the form of mild conjunctival follicular					hypertrophy.<xref ref-type="bibr" rid="ref62">62</xref>,<xref ref-type="bibr" rid="ref63">63</xref> Patients may complain of					photophobia and grittiness.<xref ref-type="bibr" rid="ref3">3</xref> Vision loss is secondary to keratitis.</p><p>Diagnosis is by Gram or Giemsa stain and spores from					conjunctival scrapings or corneal biopsies can be easily seen					with Masson trichrome or Giemsa stain. Immunofluorescence					and electron microscopy can help confirm the diagnosis.<xref ref-type="bibr" rid="ref3">3</xref>					Ocular microsporidiasis should be suspected in all HIV-positive					patients with persistently negative cultures for epithelial					keratitis. Although HAART has been shown to alleviate and					resolve microsporidial keratoconjunctivitis in HIV-positive					hosts<xref ref-type="bibr" rid="ref64">64</xref>,<xref ref-type="bibr" rid="ref65">65</xref> post-immune recovery-mediated					microsporidial keratoconjunctivitis reactivation has also been reported.<xref ref-type="bibr" rid="ref66">66</xref></p><p>Treatment:<xref ref-type="bibr" rid="ref67">67</xref> Fumagillin 70 mg/mL eye drops are used					indefinitely in HIV-positive individuals. Albendazole 400 mg					twice daily orally should be used as an adjunct for the					management of systemic infection.</p></sec><sec><title>Toxoplasmosis</title><p><italic>Toxoplasma gondii</italic> can cause necrotizing retinochoroiditis					with associated anterior uveitis as secondary phenomena,					but the parasite does not extend beyond the neural retina. In					contrast, severely immunosuppressed individuals with AIDS					can develop a primary toxoplasmic anterior uveitis, which can					occur in the absence of retinal lesions. Iris nodules with tissue					destruction and severe anterior segment inflammation have					been noted.<xref ref-type="bibr" rid="ref68">68</xref> Inflammation responds well to anti-parasitic					therapy but not to corticosteroids alone.</p></sec></sec><sec><title>Mycobacterial disease</title><p>Tuberculosis (TB) implies the presence of active disease from					infection with the acid-fast bacillus.<xref ref-type="bibr" rid="ref69">69</xref> <italic>Mycobacterium tuberculosis</italic>					is the commonest systemic opportunistic infection associated					with AIDS even though ocular TB is not as common.<xref ref-type="bibr" rid="ref70">70</xref> It is					important to consider it as a differential diagnosis, especially					in India.</p><p>Bouza <italic>et al</italic>.<xref ref-type="bibr" rid="ref17">17</xref> reported an unusually high (18%) incidence					of ocular tuberculosis in a cohort of 100 randomly selected					tuberculosis patients examined systematically for ocular					tuberculosis from 300 culture proven cases for acid fast bacilli.					Eleven of these patients were HIV positive. Eleven patients had					no symptoms attributable to ocular tuberculosis.</p><p><italic>M. avium</italic>, a species of nontuberculous mycobacteria, was					reported to be the cause of endophthalmitis<xref ref-type="bibr" rid="ref72">72</xref> with an intense					inflammatory reaction and hypopyon in an individual with					AIDS who had a history of disseminated <italic>M. avium</italic> infection.					Prominent iris nodules caused by <italic>M. avium</italic> complex (MAC)					has also been observed as the initial manifestation of					panophthalmitis in an individual with AIDS.</p><p>Changed presentation in the setting of HIV disease is not					known, especially in case of anterior segment lesions in TB.<xref ref-type="bibr" rid="ref9">9</xref>					Clinical manifestations include ulcers, tubercles, granular					masses or pedunculated polypoid tumors.<xref ref-type="bibr" rid="ref9">9</xref> Patients may					present with localized nodule in the eyelid simulating chalazion.					Orbital and lacrimal gland involvement by <italic>M. tuberculosis</italic> leads					to localized granuloma<xref ref-type="bibr" rid="ref73">73</xref> though unusually they can present as					a conjunctival mass.<xref ref-type="bibr" rid="ref70">70</xref></p><p>Infection of the iris can present either with or without					iris nodules. TB is also a known cause of uveitis, although					it is uncommon, even among those with systemic TB.<xref ref-type="bibr" rid="ref71">71</xref>					Presentations of ocular tuberculosis in HIV-infected individuals					is also similar. An association between corneal phlyctenulosis<xref ref-type="bibr" rid="ref74">74</xref>					and tuberculoprotein hypersensitivity is suggested by both					epidemiologic and experimental studies, although it is rarely					seen in patients with pulmonary TB.</p><p>TB may cause interstitial keratitis with stromal infiltration.					Interstitial keratitis secondary to TB may be associated with					uveitis. It may occur as an isolated finding or in association with					scleritis. Sclerokeratitis can be seen with peripheral stromal					inflammation in a triangular fashion associated with localized					scleritis. Localized lesions are focal elevated nodules of the					sclera that may undergo necrosis leading to scleromalacia and					scleral perforation if untreated. Diffuse scleritis is less common					than localized nodular scleritis.</p><p><italic>M. tuberculosis</italic> infection of the conjunctiva may involve					the palpebral, bulbar, or forniceal conjunctiva. Tuberculous					conjunctivitis is a very rare condition in the developed world.					In recalcitrant cases of chronic red eye,<xref ref-type="bibr" rid="ref75">75</xref> a definitive diagnosis					requires the identification of <italic>Mycobacterium tuberculosis</italic>					organisms in conjunctival biopsy specimens, either through					microscopic detection of acid-fast bacilli or through more					sensitive culture techniques. Keratoconjunctivitis may occur					in association with cutaneous TB.<xref ref-type="bibr" rid="ref76">76</xref> While intraocular disease					is mostly a secondary infection, cutaneous TB is almost always					primary.<xref ref-type="bibr" rid="ref77">77</xref></p><p>Tuberculosis can present as a granulomatous type of anterior					uveitis, even in HIV-infected individuals and the inflammatory					reaction correlates with the level of CD4 cell counts.</p><p>Treatment: Systemic anti-tuberculous therapy (ATT)					with drugs such as isoniazid, rifampin, pyrazinamide and					ethambutol is important as pulmonary or other foci of disease					may coexist. Modified DOTS regimen (Directly Observed					Treatment Short course) is the recommended regime in India.					Specific ocular treatment should be instituted along with ATT.					There have been reports of scleral TB responding favorably to					additional topical (every 2 h) and subconjunctival (every three					days) streptomycin sulfate along with ATT<xref ref-type="bibr" rid="ref9">9</xref> with healing of the					lesion. In individuals with HIV infection, therapy may require					longer duration and additional drugs. Newer drugs have also					been incorporated in the ATT group of drugs, especially in the					newer setting of multidrug-resistant TB, particularly in case					of HIV-infected individuals. These include quinolones, newer					rifamycins like rifabutin and macrolides antibiotics.</p></sec><sec><title>Fungal infections</title><p>In the general population, fungal corneal ulcers are rare in					the absence of preceding trauma, ocular surface disease or					corticosteroid therapy while HIV/AIDS patients can develop					spontaneous fungal infections. In developed countries, <italic>Candida</italic>					and cryptococci are the most prevalent ocular fungal pathogens					among HIV-positive hosts. <italic>Candida</italic> causes anterior segment					keratitis. <italic>Cryptococci</italic> commonly triggers posterior segment					pathology although they can sometimes cause conjunctivitis,					limbal infection and iris granulomas.<xref ref-type="bibr" rid="ref78">78</xref> <italic>Cryptococcus albidus</italic>					causing scleral ulceration has been reported.<xref ref-type="bibr" rid="ref79">79</xref> <italic>Histoplasma</italic> and					<italic>Pneumocystis</italic> can also cause anterior segment manifestations<xref ref-type="bibr" rid="ref9">9</xref>					but are not as commonly reported from India. Fungal					keratitides have a more acute and protracted course in the					HIV/AIDS population, and are more likely to result in bilateral					disease with corneal perforation.<xref ref-type="bibr" rid="ref80">80</xref> Hence, culture or biopsy					of lesions is important for HIV-infected patients with ocular					surface infections, to differentiate between bacterial and fungal					etiology.</p></sec><sec><title>Spirochaetal infections</title><p><italic>Treponema pallidum:</italic> Ocular syphilis caused by <italic>Treponema					</italic> <italic>pallidum</italic> tends to present with more aggressive, severe and					relapsing manifestations in HIV-positive hosts as compared					with immunocompetent hosts.<xref ref-type="bibr" rid="ref81">81</xref>-<xref ref-type="bibr" rid="ref83">83</xref> It is frequently the					presenting symptom of co-infection with HIV. All patients with syphilis					should be evaluated for HIV and vice versa, as syphilis may					follow a more aggressive course in individuals who are					concurrently infected with HIV. Disruption of the mucosal					epithelial barrier in syphilitic ulcers, which contain mononuclear					cells (targets of HIV infection) may be the mechanism by which					syphilis increases the risk of HIV acquisition.<xref ref-type="bibr" rid="ref9">9</xref> Anterior segment					manifestations of syphilis include chancres of the conjunctiva					(primary syphilis), conjunctivitis (secondary syphilis) and					gummata (late syphilis). Conjunctivitis can be granulomatous					and histologically similar to sarcoidosis.<xref ref-type="bibr" rid="ref9">9</xref></p><p>It is the most common bacterial cause of uveitis in HIV-					positive hosts with an incidence of 0.6%. It tends to be more					severe and consists of panuveitis in conjunction with anterior					uveitis.<xref ref-type="bibr" rid="ref82">82</xref>,<xref ref-type="bibr" rid="ref83">83</xref> Eighty-five per cent of HIV-positive					patients with ophthalmic syphilis have coexisting neurosyphilis, and hence					all patients must undergo cerebrospinal fluid analysis to rule					out neurosyphilis when syphilitic uveitis is first diagnosed.<xref ref-type="bibr" rid="ref84">84</xref>					The diagnosis of syphilis involves a good clinical history in					addition to serologic screening and confirmatory tests such as					the rapid plasma reagin or fluorescent treponemal antibody					absorbent tests, respectively. Direct examination using darkfield					microscopy or biopsy of suspicious lesions can be performed					if results are uncertain.<xref ref-type="bibr" rid="ref85">85</xref> Isolated episcleritis and scleritis are					uncommon during any stage of the disease, but when present,					are usually features of secondary or late syphilis.<xref ref-type="bibr" rid="ref86">86</xref></p><p>Treatment of ocular syphilis is similar to that of neurosyphilis.					The most effective treatment involves high-dose IV penicillin					G 12 to 24 million units/d for 14 days.<xref ref-type="bibr" rid="ref87">87</xref>,<xref ref-type="bibr" rid="ref88">88</xref> Because					of the high rate of relapse, HIV-positive patients are recommended to have					extensive follow-up subsequently at least for two years.</p><p>Anterior uveitis<xref ref-type="bibr" rid="ref2">2</xref>: Anterior uveitis may be rarely associated					with HIV disease, especially as part of a CMV retinitis (CMVR)					or a syphilitic panuveitis. Symptomatic anterior uveitis is rare					in HIV-positive patients.<xref ref-type="bibr" rid="ref88">88</xref> Uveitis associated with CMVR					is seen rarely. More severe anterior chamber inflammation					may be seen with toxoplasmic or syphilitic retinochoroiditis/					panuveitis,<xref ref-type="bibr" rid="ref89">89</xref> or rarely in other infectious retinitis such as acute					retinal necrosis.</p><p>HIV itself has been isolated from tears, conjunctiva, cornea,					aqueous humor, iris, sclera, vitreous humor and retina, and					has been suspected as a cause of intraocular inflammation					occasionally, in the absence of other pathogens.<xref ref-type="bibr" rid="ref9">9</xref></p><p>&#x02033;Multifocal punctate retinal infiltrates,&#x02033; an unusual					inflammatory condition, which can have associated anterior					segment inflammation, may also be a direct effect of HIV					infection.<xref ref-type="bibr" rid="ref90">90</xref> Diagnosis requires slit-lamp examination, and					therapy is primarily directed at identifying an infectious					etiology. Topical steroids are often employed but must be					used with caution and in combination with appropriate					antimicrobial therapy.</p></sec><sec><title>Other adnexal infectious lesions</title><sec><title>Preseptal cellulitis</title><p><italic>Staphylococcus aureus</italic> is the most common cause of cutaneous							and systemic bacterial infection in HIV-positive patients. It is							found in the nasal mucosa in more than twice<xref ref-type="bibr" rid="ref91">91</xref> the number of							HIV patients when compared to normal individuals. Treatment							is similar to that in immunocompetent individuals.</p></sec></sec></sec><sec sec-type=""><title>Abscess in the eyelid</title><p>Infections of the eyelid and conjunctiva are rare in patients with			AIDS. Dermal abscesses due to <italic>staphylococci</italic>, acid-fast bacilli			and CMV have been reported in molluscum lesions in patients			with AIDS indicating the tendency of such lesions to acquire			secondary infection.<xref ref-type="bibr" rid="ref53">53</xref>,<xref ref-type="bibr" rid="ref92">92</xref> Diagnosis is by smear and			culture.</p><p>Treatment: Topical and systemic antibiotics.</p></sec><sec sec-type=""><title>Neoplasms</title><sec><title>Kaposi&#x02032;s sarcoma of the eyelid and the conjunctiva</title><p>Kaposi&#x02032;s sarcoma (KS) is a highly vascular mesenchymal				tumor that appears as multiple purple-to-red nodules on the				skin and mucous membranes<xref ref-type="bibr" rid="ref31">31</xref> [<xref ref-type="fig" rid="F3">Figure 3</xref>]. It occurs in				30% of all AIDS patients in the US. In approximately 10-20% of				individuals with HIV-associated KS, the tumor involves the				eyelids, conjunctiva and in rare cases, the orbit. KS can be an				initial manifestation of AIDS. Kaposi&#x02032;s sarcoma of the eyelid				and conjunctiva is rare in the Indian subcontinent possibly due				to the rarity of the probable causative agent, human herpes				virus 8. The appearance of KS on the eyelids is similar to the				lesions elsewhere on the skin. It can mimic a chalazion and can				be seen in the upper or lower lids. Conjunctival lesions<xref ref-type="bibr" rid="ref93">93</xref>,<xref ref-type="bibr" rid="ref94">94</xref> may be seen in any part of the palpebral or bulbar conjunctiva but are				usually more common in the inferior fornix. Kaposi&#x02032;s sarcoma				in the conjunctiva can be mistaken for a subconjunctival				hemorrhage or pyogenic granuloma.<xref ref-type="bibr" rid="ref4">4</xref></p><p>Histologically, KS can resemble an angioma, hemangioma,				lymphangioma or granulation tissue. It has a complex				arrangement of capillary channels and vascular spaces (&#x02033;slits&#x02033;)				without endothelium.<xref ref-type="bibr" rid="ref9">9</xref> Malignant spindle cells are arranged				around these incomplete vascular spaces. The spindle-				shaped interstitial cells are of vascular endothelial origin,				with vacuolated cytoplasm which may demonstrate mitotic				activity.<xref ref-type="bibr" rid="ref95">95</xref> Dugel and associates<xref ref-type="bibr" rid="ref96">96</xref> have classified				adnexal KS lesions clinically and histopathologically into three stages.				Stage I and II lesions are flat (less than 3 mm in height), patchy				and of less than four months duration; Stage III lesions are				nodular, greater than 3 mm in height and greater than four				months in duration. This staging may have prognostic value				regarding the course of disease and response to therapy.<xref ref-type="bibr" rid="ref97">97</xref></p><p>Treatment: KS does not invade the eye and treatment is not				necessary if it is asymptomatic and is cosmetically acceptable.				The principal goal of therapy in this population is palliation				when disease is disfiguring, painful, or interfering with function.				Local measures are often used for patients with minimal				cutaneous KS.<xref ref-type="bibr" rid="ref9">9</xref> However, if it causes discomfort either through				a mass effect, secondary corneal change or if it is disfiguring,				then treatment can be planned. Under these circumstances, it				may be treated by cryotherapy, surgical excision (if the lesion				is small), radiation and/or chemotherapy.</p><p>Radiation therapy<xref ref-type="bibr" rid="ref11">11</xref> is effective in treating the eyelid and				conjunctival lesions but can lead to loss of lashes, irritation,				conjunctivitis, conjunctival keratinization, cicatricial ectropion				and retinopathy.</p><p>Systemic agents are warranted for patients with advanced				disease such as extensive cutaneous disease, visceral disease				or lymphedema. Intralesional vinblastin or interferon alpha<xref ref-type="bibr" rid="ref12">12</xref>				have known to produce good results. Associated systemic KS				is best treated with systemic chemotherapy. Anterior segment				fluorescein angiography can be helpful in demarcating the 1				to 2 mm tumor-free zone during surgery. Magnetic resonance				imaging can be helpful in the diagnosis and follow-up of				patients after treatment.<xref ref-type="bibr" rid="ref98">98</xref></p><p>Widespread success of HAART in treating AIDS-related				primary KS has definitely reduced the need for other				management options too, controlling the disease such as				chemotherapy or irradiation.<xref ref-type="bibr" rid="ref99">99</xref></p><p>Immune reconstitution inflammatory syndrome-related				complications causing lethal KS have been reported. Early				intervention with a limited course of systemic chemotherapy				(while still maintaining a HAART regimen) is successful in				treating the flare-ups<xref ref-type="bibr" rid="ref100">100</xref>,<xref ref-type="bibr" rid="ref101">101</xref></p></sec><sec><title>Squamous cell carcinoma of conjunctiva</title><p>SCC is the third most common neoplasm associated with				HIV after KS and lymphoma.<xref ref-type="bibr" rid="ref3">3</xref> The eyelid and conjunctiva are				seldom a site of initial presentation in the developed world				though they can be the first presenting sign of AIDS in up to				50% of African patients though it is not as common in the Indian				population<xref ref-type="bibr" rid="ref102">102</xref>-<xref ref-type="bibr" rid="ref104">104</xref> [<xref ref-type="fig" rid="F4">Figure 4</xref>]. Africans are more at risk due to the				increased prevalence of the human papilloma virus.</p><p>When the tumor is found at the limbus, gonioscopy has to be				performed to rule out intraocular extension.<xref ref-type="bibr" rid="ref2">2</xref> Most commonly				noted clinical characteristics of conjunctival SCC are corneal				overriding (90%), fast growth rates (with a rate of 1mm in 83%),				tumors larger than 1 cm (17%), changes in conjunctival color				(66%), and nasal locations (66%).<xref ref-type="bibr" rid="ref3">3</xref></p><p>Twenty percent of benign pterygia may harbour SCC/				Carcinoma <italic>in situ</italic> and hence pathology review should be done				for all conjunctival lesions. HIV testing should be carried out in				all cases of conjunctival tumors for patients living in high-risk				areas as it may be the first sign of HIV-positivity.<xref ref-type="bibr" rid="ref104">104</xref></p><p>Treatment: Wide excision with frozen section monitoring				of the margins. HAART has been known to cause complete				regression of invasive conjunctival SCC in an HIV-positive				patient,<xref ref-type="bibr" rid="ref105">105</xref> which raises the possibility of antiviral therapy as				an alternative to radical surgery.</p></sec><sec><title>Cutaneous and conjunctival lymphoma<xref ref-type="bibr" rid="ref2">2</xref></title><p>Non-Hodgkin&#x02032;s lymphoma (NHL) accounts for 3.5&#x02013;5% of				AIDS-defining illnesses<xref ref-type="bibr" rid="ref9">9</xref> and tends to be of a higher grade				of malignancy in HIV patients<xref ref-type="bibr" rid="ref106">106</xref> and can affect eyelids and				conjunctiva. NHL should be suspected in all HIV patients of				any age who have prominent vitreous cells, with or without				subretinal exudation. Intraocular lymphoma usually is seen with				CD4 cell counts of less than 50 cells/ml. Intraocular lymphoma				can also cause anterior chamber reactions.<xref ref-type="bibr" rid="ref107">107</xref>,<xref ref-type="bibr" rid="ref108">108</xref>				Primary NHL has also been found in eyelids of patients with AIDS, presenting				as rapidly enlarging erythematous lesions.<xref ref-type="bibr" rid="ref109">109</xref> Lid swelling,				ptosis, proptosis, gaze palsies and ophthalmoplegia have been				reported.<xref ref-type="bibr" rid="ref110">110</xref> NHL can mimic keratoconjunctivitis sicca. Hence				any AIDS patient with dry eye, especially if unresponsive to				therapy, should be viewed with suspicion, more so, if it is				unilateral and/or the patient has associated systemic symptoms				such fever, malaise or weight loss.<xref ref-type="bibr" rid="ref2">2</xref></p><p>Treatment: Radiotherapy and/or chemotherapy such as				vinblastin. Interferon alpha has also been used as part of				treatment modality.</p></sec><sec><title>Bacillary angiomatosis</title><p>Bacillary angiomatosis (BA)<xref ref-type="bibr" rid="ref111">111</xref>,<xref ref-type="bibr" rid="ref112">112</xref> is the				vascular proliferative form of infection with <italic>Bartonella</italic> organisms. Bacillary				angiomatosis was first described in 1983 in a patient infected				with the HIV. Subsequently, it has been described in patients				following organ transplants and in other immunocompromised				persons. Patients with HIV disease are at increased risk of				developing BA when their CD4 T-cell count &#x0003c;200 cells/cu.mm. It				can mimic KS and is important that this entity is differentiated				from the more lethal KS.</p></sec><sec><title>Other manifestations</title><sec><title>Keratoconjunctivitis sicca (KCS)</title><p>Dry eye occurs in 20&#x02013;38.8% of HIV-positive hosts in the						later stages of AIDS.<xref ref-type="bibr" rid="ref3">3</xref> It is thought to be due to lymphocytic						infiltration of the lacrimal gland. Afflicted individuals are						more susceptible to bacterial keratitis and abnormalities in the						composition of the tear film are typically present.<xref ref-type="bibr" rid="ref113">113</xref> Etiology						is multifactorial and is due to the combined effects of HIV-						mediated inflammatory destruction of primary and accessory						lacrimal glands and to the direct conjunctival damage due to						the HIV virus itself.<xref ref-type="bibr" rid="ref112">112</xref> The virus is also postulated to play a						significant role in spontaneous corneal thinning and perforation						which is observed in some infected patients.<xref ref-type="bibr" rid="ref114">114</xref>-<xref ref-type="bibr" rid="ref116">116</xref>						Contrary to its effect on many other ocular HIV/AIDS-related diseases,						HAART has not played a part in significantly reducing the						prevalence of KCS.<xref ref-type="bibr" rid="ref3">3</xref></p><p>Management options include artificial tears, long-acting						lubricants and punctal occlusion in severe cases.</p></sec><sec><title>Conjunctivitis</title><p>Non-specific, culture-negative conjunctivitis has been reported						to be seen in less than 1% of patients with HIV.<xref ref-type="bibr" rid="ref2">2</xref> Rarely						<italic>cytomegalovirus</italic> or <italic>cryptococcus</italic> can be the causative organism.						Grams stain and culture need to be done before labeling it as						non-infective. Biopsy is indicated in unresponsive cases.</p></sec><sec><title>Trichomegaly</title><p>Acquired trichomegaly or hypertrichosis<xref ref-type="bibr" rid="ref2">2</xref> have been described,						especially in the late stages. Exact cause is not known although						drug toxicity,<xref ref-type="bibr" rid="ref117">117</xref> elevated viral load have been suggested to						play a role. It has to be treated if annoying or if cosmetically						unacceptable.</p></sec><sec><title>Conjunctival microvasculopathy</title><p>Seventy to eighty per cent patients have some form of						asymptomatic conjunctival microvascular changes. These						include segmental vascular dilatation and narrowing,						microaneurysm formation, comma-shaped vascular fragment						and visible granularity to the flowing blood column (sludging).<xref ref-type="bibr" rid="ref2">2</xref>						These are seen more commonly near the inferior limbus						and have a good correlation with the occurrence of retinal						microvasculopathy. Exact cause is not known. It is postulated						to be due to increased plasma viscosity, endothelitis or immune						complex deposition. No treatment is required</p></sec><sec><title>Angle closure glaucoma<xref ref-type="bibr" rid="ref2">2</xref></title><p>Acute angle closure glaucoma has been described in association						with uveal effusion<xref ref-type="bibr" rid="ref118">118</xref> syndrome in patients infected with HIV.						Cause of angle closure glaucoma is not known. Intraocular						inflammation is minimal but can be severe in case of						primary choroidal inflammation with secondary exudative						retinal detachment. B-scan ultrasonography and ultrasound						biomicroscopy helps in clinching the diagnosis. Treatment						includes cycloplegics, corticosteroids, aqueous suppressants,						hyperosmolar agents and surgical drainage of suprachoroidal						fluid.</p></sec><sec><title>Atopic Dermatitis</title><p>Atopic dermatitis has a prevalence of approximately 10% in the						general population and can be the first ocular manifestation						in some individuals after HIV infection.<xref ref-type="bibr" rid="ref9">9</xref> Treatment of						atopic eyelid disease in both HIV-infected and HIV-negative						individuals consists of topical corticosteroids.</p></sec><sec><title>Blepharitis</title><p>Blepharitis is more common and more serious in HIV-infected						individuals. Blepharitis and an eyelid ulcer have been reported						as the initial manifestations of HIV disease<xref ref-type="bibr" rid="ref92">92</xref> [<xref ref-type="fig" rid="F5">Figure						5</xref>]. New-onset chronic relapsing episodes of blepharitis, which began						months to years after starting indinavir therapy have also been						reported. These patients presented with retinoid effects such						as desquamative or erosive chelitis, mucocutaneous xerosis,						alopecia, asteatotic eczema, paronychia, and ingrown nails.<xref ref-type="bibr" rid="ref119">119</xref></p></sec></sec></sec><sec sec-type=""><title>Iatrogenic and post-treatment manifestations</title><sec><title>Immune recovery uveitis</title><p>The clinical picture of HIV-associated eye disease has changed			dramatically since the introduction of HAART.<xref ref-type="bibr" rid="ref8">8</xref> Although direct			infectious destruction of tissue is less severe, inflammatory			infiltration is augmented, and this gives rise to a situation			that is open to misinterpretation. Before the introduction			of protease inhibitors, patients with CMV retinitis typically			had CD4 T-lymphocyte counts less than 50 cells/cu.mm with			minimal intraocular inflammation.<xref ref-type="bibr" rid="ref120">120</xref>,<xref ref-type="bibr" rid="ref121">121</xref>			Significant intraocular inflammation has now been reported in some patients with			CMV retinitis who have had improved immune function			with HAART [<xref ref-type="fig" rid="F6">Figure 6</xref>]. Immune recovery uveitis, which			involves mainly the anterior uvea and vitreous, is often			associated with a marked disturbance of visual function.<xref ref-type="bibr" rid="ref122">122</xref>,<xref ref-type="bibr" rid="ref123">123</xref> Hence it is important to identify early the occurrence of this			phenomenon in patients on HAART on their path to immune			recovery. Prompt treatment with anti-inflammatory therapy			including steroids prevents vision loss due to immune recovery			uveitis.</p></sec><sec><title>Drug-induced uveitis</title><p>Another group of new diseases has been attributed to the toxic			effects of drugs, i.e. of Rifabutin<xref ref-type="bibr" rid="ref124">124</xref> and Cidofovir.<xref ref-type="bibr" rid="ref125">125</xref> In both instances, a predominantly anterior form of uveitis develops,			which is characterized by a discrepancy between clinical			symptoms and morphological changes; the former condition			is distinguished by severe pain, and the latter by marked			inflammation.</p><p>Certain autoimmune syndromes (such as Reiter&#x02032;s syndrome)			may also be associated with iridocyclitis. Rare occurrences of an			anterior uveitis secondary to sarcoidosis<xref ref-type="bibr" rid="ref126">126</xref> in a patient infected			with HIV have been reported.</p><p>Symptomatic anterior uveitis in HIV-positive patients has			been described by Verma <italic>et al</italic>.<xref ref-type="bibr" rid="ref127">127</xref> They reported 12 cases with			varied etiology. They concluded that HIV-positive patients			with symptoms of uveitis do not have active CMV retinitis and			the ophthalmologist must search for other causes such as TB			or lymphoma in those with granulomatous uveitis or herpes			zoster in those with non-granulomatous uveitis.</p></sec></sec><sec sec-type=""><title>Stevens-Johnson syndrome (SJS)</title><p>HIV-infected individuals are frequently exposed to many		medications, especially drugs such as nevirapine, which are		capable of causing hypersensitivity or toxic reactions. Altered		cell-mediated immunity may also lead to increased risk of		SJS as a response to infectious agents as well. Associated dry		eye may aggravate the problems associated with SJS in HIV-		infected individuals.<xref ref-type="bibr" rid="ref9">9</xref></p></sec><sec sec-type=""><title>Corneal phospholipidoses<xref ref-type="bibr" rid="ref2">2</xref></title><p>Vortex keratopathy or corneal phospholipidosis can be caused		by antivirals such as ganciclovir, acyclovir or atovaquone, a		drug used in the treatment of toxoplasmosis. Patients may be		asymptomatic or may complain of a mild irritation, foreign		body sensation or photophobia. Characteristic whorl-like		pattern of gray white opacities is seen at the level of the corneal		epithelium.</p></sec><sec sec-type=""><title>Summary</title><p>Anterior segment manifestations in the eye in HIV-infected		individuals are varied. They can be vision-threatening. More		commonly, they can affect the quality of life which ultimately		hampers the rehabilitation of the individual which is the		ultimate goal. Multiple pathogens can be found in the same		individual. They can give a definitive clue to HIV-related		systemic disorder. As is the case with other lesions, even		anterior segment and adnexal manifestations in these patients		may have atypical presentations. They may present with		minimal inflammatory reactions and thus every clinician		should be aware of such atypical manifestations.</p><p>In India, viral infections, such as herpes <italic>zoster</italic>, herpes <italic>simplex</italic>		and molluscum contagiosum are more common. Patients with		herpetic eye disease in AIDS may need long-term maintenance		prophylaxis therapy. Herpes zoster ophthalmicus is seen		relatively more commonly in the HAART era in India.</p><p>HAART has definitely reduced the frequency of rare		malignancies such as KS and SCC though ocular KC is not		commonly seen in India. There are not many studies regarding		the prevalence of other anterior segment manifestations in		HIV-infected individuals in India.</p><p>Patients on HAART can develop severe inflammatory		reaction due to immune recovery phenomenon which can		cause severe ocular morbidity. Hence it is important that		ophthalmologists be aware of this emerging new phenomenon		so that it is managed appropriately.</p></sec></body><back><fn-group><fn><p>Source of Support: Nil</p></fn><fn><p>Conflict of Interest: None declared</p></fn></fn-group><ref-list><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodge</surname><given-names>WG</given-names></name><name><surname>Seif</surname><given-names>SR</given-names></name><name><surname>Margolis</surname><given-names>TP</given-names></name></person-group><article-title>Ocular opportunistic infectionincidences among patients who are HIV positive compared topatients who are HIV negative</article-title><source>Ophthalmology</source><year>1998</year><volume>105</volume><fpage>895</fpage><lpage>900</lpage><pub-id pub-id-type="pmid">9593394</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kestelyn</surname><given-names>PG</given-names></name><name><surname>Cunningham</surname><given-names>ET</given-names><suffix>Jr</suffix></name></person-group><article-title>HIV-AIDS and blindness</article-title><source>Bull World Health Organ</source><year>2001</year><volume>79</volume><fpage>208</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">11285664</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><article-title>Adnexal and anterior segment manifestations of HIV-AIDS</article-title><source>Int Ophthalmol Clin</source><year>2007</year><volume>47</volume><fpage>15</fpage><lpage>32</lpage></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>D</given-names></name></person-group><article-title>Eye signs that alert the clinician to a diagnosis of AIDS</article-title><source>SADJ</source><year>2005</year><volume>60</volume><fpage>386</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">16320530</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahraman</surname><given-names>G</given-names></name><name><surname>Krepler</surname><given-names>K</given-names></name><name><surname>Franz</surname><given-names>C</given-names></name><name><surname>Ries</surname><given-names>E</given-names></name><name><surname>Maar</surname><given-names>N</given-names></name><name><surname>Wedrich</surname><given-names>A</given-names></name><etal/></person-group><article-title>Seven years of HAART impact on ophthalmic managementof HIV-infected patients</article-title><source>Ocul Immunol Inflamm</source><year>2005</year><volume>13</volume><fpage>213</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16019681</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirk</surname><given-names>O</given-names></name><name><surname>Mocroft</surname><given-names>A</given-names></name><name><surname>Lundgren</surname><given-names>JD</given-names></name></person-group><collab>EuroSIDA-studiet</collab><article-title>Decline inAIDS and death rates in the EuroSIDA study: An observationalstudy</article-title><source>Ugeskr Laeger</source><year>2004</year><volume>166</volume><fpage>2572</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">15285167</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mesaric</surname><given-names>B</given-names></name><name><surname>Lisic</surname><given-names>M</given-names></name><name><surname>Kniewald</surname><given-names>T</given-names></name><name><surname>Ugrinovic</surname><given-names>N</given-names></name><name><surname>Begovac</surname><given-names>J</given-names></name></person-group><article-title>Ocularmanifestations in patients with human immunodeficiency virusinfection before and after the introduction of highly activeantiretroviral therapy</article-title><source>Lijec Vjesn</source><year>2005</year><volume>127</volume><fpage>123</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16281473</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arruda</surname><given-names>RF</given-names></name><name><surname>Muccioli</surname><given-names>C</given-names></name><name><surname>Belfort</surname><given-names>R</given-names><suffix>Jr</suffix></name></person-group><article-title>Ophthalmological findingsin HIV infected patients in the post-HAART (Highly ActiveAnti-retroviral Therapy) era, compared to the pre-HAART era</article-title><source>Rev Assoc Med Bras</source><year>2004</year><volume>50</volume><fpage>148</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">15286861</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeng</surname><given-names>BH</given-names></name><name><surname>Holland</surname><given-names>GN</given-names></name><name><surname>Lowder</surname><given-names>CY</given-names></name><name><surname>Deegan</surname><given-names>WF</given-names><suffix>3rd</suffix></name><name><surname>Raizman</surname><given-names>MB</given-names></name><name><surname>Meisler</surname><given-names>DM</given-names></name></person-group><article-title>Anterior segment and external ocular disordersassociated with human immunodeficiency virus disease</article-title><source>Surv Ophthalmol</source><year>2007</year><volume>52</volume><fpage>329</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">17574062</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="webpage"><date-in-citation>last accessed on 2006 May 13</date-in-citation><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.unaids.org-epi-2005-doc-report_pdf.asp">http://www.unaids.org-epi-2005-doc-report_pdf.asp</ext-link></comment></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belfort</surname><given-names>R</given-names><suffix>Jr</suffix></name></person-group><article-title>The ophthalmologist and the global impact of the AIDSepidemic: LV Edward Jackson Memorial lecture</article-title><source>Am J Ophthalmol</source><year>2000</year><volume>129</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">10653405</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ratnam</surname><given-names>I</given-names></name><name><surname>Chiu</surname><given-names>C</given-names></name><name><surname>Kandala</surname><given-names>NB</given-names></name><name><surname>Easterbrook</surname><given-names>PJ</given-names></name></person-group><article-title>Incidence andrisk factors for immune reconstitution inflammatory syndrome inan ethnically diverse HIV type 1-infected cohort</article-title><source>Clin Infect Dis</source><year>2006</year><volume>42</volume><fpage>418</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">16392092</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>French</surname><given-names>MA</given-names></name><name><surname>Price</surname><given-names>P</given-names></name><name><surname>Stone</surname><given-names>SF</given-names></name></person-group><article-title>Immune restoration disease afterantiretroviral therapy</article-title><source>AIDS</source><year>2004</year><volume>18</volume><fpage>1615</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">15280772</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooney</surname><given-names>EL</given-names></name></person-group><article-title>Clinical indicators of immune restoration followinghighly active antiretroviral therapy</article-title><source>Clin Infect Dis</source><year>2002</year><volume>34</volume><fpage>224</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">11740712</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jabs</surname><given-names>DA</given-names></name><name><surname>Bartlett</surname><given-names>JG</given-names></name></person-group><article-title>AIDS and Ophthalmology: A period of transition</article-title><source>Am J Ophthalmol</source><year>1997</year><volume>124</volume><fpage>227</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">9262548</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liesegang</surname><given-names>TJ</given-names></name></person-group><article-title>Varicella-zoster virus eye disease</article-title><source>Cornea</source><year>1999</year><volume>18</volume><fpage>511</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">10487424</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biswas</surname><given-names>J</given-names></name><name><surname>Samanta</surname><given-names>TK</given-names></name><name><surname>Madhavan</surname><given-names>HN</given-names></name><name><surname>Kumarasamy</surname><given-names>N</given-names></name><name><surname>Solomon</surname><given-names>S</given-names></name></person-group><article-title>Acute panuveitis with haemorrhagic hypopyon as a presentingfeature of acquired immunodeficiency syndrome (AIDS)</article-title><source>Indian J Ophthalmol</source><year>2000</year><volume>48</volume><fpage>311</fpage><lpage>2</lpage><pub-id pub-id-type="pmid">11340891</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sellitti</surname><given-names>TP</given-names></name><name><surname>Huang</surname><given-names>AJ</given-names></name><name><surname>Schiffman</surname><given-names>J</given-names></name><name><surname>Davis</surname><given-names>JL</given-names></name></person-group><article-title>Association of herpeszoster ophthalmicus with acquired immunodeficiency syndromeand acute retinal necrosis</article-title><source>Am J Ophthalmol</source><year>1993</year><volume>116</volume><fpage>297</fpage><lpage>301</lpage><pub-id pub-id-type="pmid">8357053</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharvadze</surname><given-names>L</given-names></name><name><surname>Tsertsvadze</surname><given-names>T</given-names></name><name><surname>Gochitashvili</surname><given-names>N</given-names></name><name><surname>Bolokadze</surname><given-names>N</given-names></name><name><surname>Dolmazashvili</surname><given-names>E</given-names></name></person-group><article-title>Peculiarities of herpes zoster in immunocompetentand immunocompromised hosts</article-title><source>Georgian Med News</source><year>2006</year><volume>141</volume><fpage>50</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">17261887</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaal</surname><given-names>MJ</given-names></name><name><surname>Volker-Dieben</surname><given-names>HJ</given-names></name><name><surname>Wienesen</surname><given-names>M</given-names></name><name><surname>D&#x02032;Amaro</surname><given-names>J</given-names></name><name><surname>Kijlstra</surname><given-names>A</given-names></name></person-group><article-title>Longitudinal analysis of varicella-zoster virus DNA on theocular surface associated with herpes zoster ophthalmicus</article-title><source>Am J Ophthalmol</source><year>2001</year><volume>131</volume><fpage>25</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11162975</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Severson</surname><given-names>EA</given-names></name><name><surname>Baratz</surname><given-names>KH</given-names></name><name><surname>Hodge</surname><given-names>DO</given-names></name><name><surname>Burke</surname><given-names>JP</given-names></name></person-group><article-title>Herpes zosterophthalmicus in Olmsted County, Minnesota: Have systemicantivirals made a difference?</article-title><source>Arch Ophthalmol</source><year>2003</year><volume>121</volume><fpage>386</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">12617710</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biswas</surname><given-names>J</given-names></name><name><surname>Fogla</surname><given-names>R</given-names></name><name><surname>Gopal</surname><given-names>L</given-names></name><name><surname>Narayana</surname><given-names>KM</given-names></name><name><surname>Banker</surname><given-names>AS</given-names></name><name><surname>Kumarasamy</surname><given-names>N</given-names></name><etal/></person-group><article-title>Current approaches to diagnosis and management of ocularlesions in human immunodeficiency virus positive patients</article-title><source>Indian J Ophthalmol</source><year>2002</year><volume>50</volume><fpage>83</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">12194584</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandor</surname><given-names>EV</given-names></name><name><surname>Millman</surname><given-names>A</given-names></name><name><surname>Croxson</surname><given-names>TS</given-names></name><name><surname>Mildvan</surname><given-names>D</given-names></name></person-group><article-title>Herpes zosterophthalmicus in patients at risk for the acquired immune deficiencysyndrome (AIDS)</article-title><source>Am J Ophthalmol</source><year>1986</year><volume>101</volume><fpage>153</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">3484904</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>E</given-names></name><name><surname>Gatell</surname><given-names>J</given-names></name><name><surname>Moran</surname><given-names>Y</given-names></name><name><surname>Aznar</surname><given-names>E</given-names></name><name><surname>Buira</surname><given-names>E</given-names></name><name><surname>Guelar</surname><given-names>A</given-names></name><etal/></person-group><article-title>High incidence of herpes zoster in patients with AIDS soon aftertherapy with protease inhibitors</article-title><source>Clin Infect Dis</source><year>1998</year><volume>27</volume><fpage>1510</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">9868668</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biswas</surname><given-names>J</given-names></name><name><surname>Madhavan</surname><given-names>HN</given-names></name><name><surname>George</surname><given-names>AE</given-names></name><name><surname>Kumarasamy</surname><given-names>N</given-names></name><name><surname>Solomon</surname><given-names>S</given-names></name></person-group><article-title>Ocular lesions associated with HIV infection in India: A seriesof 100 consecutive patients evaluated at a referral center</article-title><source>Am J Ophthalmol</source><year>2000</year><volume>129</volume><fpage>9</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">10653406</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kost</surname><given-names>RG</given-names></name><name><surname>Straus</surname><given-names>SE</given-names></name></person-group><article-title>Postherpetic neuralgia-pathogenesis, treatmentand prevention</article-title><source>N Engl J Med</source><year>1996</year><volume>35</volume><fpage>32</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">8637540</pub-id></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vander</surname><given-names>SM</given-names></name><name><surname>Carrasco</surname><given-names>D</given-names></name><name><surname>Lee</surname><given-names>P</given-names></name><name><surname>Tyring</surname><given-names>SK</given-names></name></person-group><article-title>Reduction of postherpeticneuralgia in herpes zoster</article-title><source>J Cutan Med Surg</source><year>2001</year><volume>5</volume><fpage>409</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">11907852</pub-id></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raja</surname><given-names>SN</given-names></name><name><surname>Haythornthwaite</surname><given-names>JA</given-names></name><name><surname>Pappagallo</surname><given-names>M</given-names></name><name><surname>Clark</surname><given-names>MR</given-names></name><name><surname>Travison</surname><given-names>TG</given-names></name><name><surname>Sabeen</surname><given-names>S</given-names></name><etal/></person-group><article-title>Opioids versus antidepressants inpostherpetic neuralgia: A randomized, placebo-controlled trial</article-title><source>Neurology</source><year>2002</year><volume>59</volume><fpage>1015</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">12370455</pub-id></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rowbotham</surname><given-names>M</given-names></name><name><surname>Harden</surname><given-names>N</given-names></name><name><surname>Stacey</surname><given-names>B</given-names></name><name><surname>Bernstein</surname><given-names>P</given-names></name><name><surname>Magnus-Miller</surname><given-names>L</given-names></name></person-group><article-title>Gabapentin for the treatment of postherpetic neuralgia:A randomized controlled trial</article-title><source>JAMA</source><year>1998</year><volume>280</volume><fpage>1837</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">9846778</pub-id></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charles</surname><given-names>NC</given-names></name><name><surname>Akhtar</surname><given-names>S</given-names></name></person-group><article-title>Herpes simplex types 2 membranousconjunctivitis in acquired immune deficiency syndrome</article-title><source>Ophthal Pract</source><year>2002</year><volume>20</volume><fpage>342</fpage><lpage>4</lpage></element-citation></ref><ref id="ref31"><label>31</label><element-citation publication-type="book"><article-title>Basic and clinical science course</article-title><source>Intraocular inflammation and uveitis</source><year>2005-2006</year><publisher-loc>USA</publisher-loc><publisher-name>American Academy of Ophthalmology</publisher-name><fpage>241</fpage><lpage>62</lpage></element-citation></ref><ref id="ref32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silverstein</surname><given-names>BE</given-names></name><name><surname>Chandler</surname><given-names>D</given-names></name><name><surname>Neger</surname><given-names>R</given-names></name><name><surname>Margolis</surname><given-names>TP</given-names></name></person-group><article-title>Disciformkeratitis: A case of herpes zoster sine herpete</article-title><source>Am J Ophthalmol</source><year>1997</year><volume>123</volume><fpage>254</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">9186133</pub-id></element-citation></ref><ref id="ref33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engstrom</surname><given-names>RE</given-names></name><name><surname>Holland</surname><given-names>GN</given-names></name></person-group><article-title>Chronic herpes zoster virus keratitisassociated with the acquired immunodeficiency syndrome</article-title><source>Am J Ophthalmology</source><year>1988</year><volume>105</volume><fpage>556</fpage><lpage>8</lpage></element-citation></ref><ref id="ref34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>TL</given-names></name><name><surname>Robin</surname><given-names>JB</given-names></name><name><surname>Holland</surname><given-names>GN</given-names></name><name><surname>Hendricks</surname><given-names>RL</given-names></name><name><surname>Paschal</surname><given-names>JF</given-names></name><name><surname>Engstrom</surname><given-names>RE</given-names><suffix>Jr</suffix></name><etal/></person-group><article-title>Herpes simplex keratitis in patientswith acquired immune deficiency syndrome</article-title><source>Ophthalmology</source><year>1989</year><volume>96</volume><fpage>1476</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">2555761</pub-id></element-citation></ref><ref id="ref35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodge</surname><given-names>WG</given-names></name><name><surname>Margolis</surname><given-names>TP</given-names></name></person-group><article-title>Herpes simplex virus keratitis amongpatients who are positive or negative for human immunodeficiencyvirus: An epidemiologic study</article-title><source>Ophthalmology</source><year>1997</year><volume>104</volume><fpage>120</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">9022115</pub-id></element-citation></ref><ref id="ref36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Owoeye</surname><given-names>JF</given-names></name><name><surname>Ademola-Popoola</surname><given-names>DS</given-names></name></person-group><article-title>Herpes zoster infection and HIVseropositivity among eye patients-University of Ilorin TeachingHospital experience</article-title><source>West Afr J Med</source><year>2003</year><volume>22</volume><fpage>136</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">14529222</pub-id></element-citation></ref><ref id="ref37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pramod</surname><given-names>NP</given-names></name><name><surname>Hari</surname><given-names>R</given-names></name><name><surname>Sudhamathi</surname><given-names>K</given-names></name><name><surname>Ananadakannan</surname><given-names>K</given-names></name><name><surname>Thyagarajan</surname><given-names>SP</given-names></name></person-group><article-title>Influence of human immunodeficiency virus statuson the clinical history of herpes simplex keratitis</article-title><source>Ophthalmologica</source><year>2000</year><volume>214</volume><fpage>337</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">10965247</pub-id></element-citation></ref><ref id="ref38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hendricks</surname><given-names>RL</given-names></name></person-group><article-title>An immunologist&#x02032;s view of the herpes simplexkeratitis</article-title><source>Cornea</source><year>1997</year><volume>16</volume><fpage>503</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">9294678</pub-id></element-citation></ref><ref id="ref39"><label>39</label><element-citation publication-type="journal"><collab>Herpetic Eye Disease Study Group</collab><article-title>Oral acyclovir for herpessimplex virus eye disease: Effect on prevention of epithelial keratitisand stromal keratitis</article-title><source>Arch Ophthalmol</source><year>2000</year><volume>118</volume><fpage>1030</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">10922194</pub-id></element-citation></ref><ref id="ref40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bodaghi</surname><given-names>B</given-names></name><name><surname>Mougin</surname><given-names>C</given-names></name><name><surname>Michelson</surname><given-names>S</given-names></name><name><surname>Agut</surname><given-names>H</given-names></name><name><surname>Dighiero</surname><given-names>P</given-names></name><name><surname>Offret</surname><given-names>H</given-names></name><etal/></person-group><article-title>Acyclovir-resistant bilateral keratitis associated withmutations in the HSV-1 thymidine kinase gene</article-title><source>Exp Eye Res</source><year>2000</year><volume>71</volume><fpage>353</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10995556</pub-id></element-citation></ref><ref id="ref41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naseri</surname><given-names>A</given-names></name><name><surname>Margolis</surname><given-names>TP</given-names></name></person-group><article-title>Varicella zoster virus immune recoverystromal keratitis in a patient with AIDS</article-title><source>Br J Ophthalmol</source><year>2001</year><volume>85</volume><fpage>1390</fpage><lpage>1</lpage><pub-id pub-id-type="pmid">11702739</pub-id></element-citation></ref><ref id="ref42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>L</given-names></name><name><surname>Rao</surname><given-names>NA</given-names></name><name><surname>Keefe</surname><given-names>KS</given-names></name><name><surname>Avila</surname><given-names>CP</given-names><suffix>Jr</suffix></name><name><surname>Macdonald</surname><given-names>JC</given-names></name><name><surname>Freeman</surname><given-names>WR</given-names></name></person-group><article-title>Cytomegalovirus iritis</article-title><source>Ophthalmic Surg Lasers</source><year>1998</year><volume>29</volume><fpage>930</fpage><lpage>2</lpage><pub-id pub-id-type="pmid">9824866</pub-id></element-citation></ref><ref id="ref43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walter</surname><given-names>KA</given-names></name><name><surname>Coulter</surname><given-names>VL</given-names></name><name><surname>Palay</surname><given-names>DA</given-names></name><name><surname>Taravella</surname><given-names>MJ</given-names></name><name><surname>Grossniklaus</surname><given-names>HE</given-names></name><name><surname>Edelhauser</surname><given-names>HF</given-names></name></person-group><article-title>Corneal endothelial deposits in patients withcytomegalovirus retinitis</article-title><source>Am J Ophthalmol</source><year>1996</year><volume>121</volume><fpage>391</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">8604732</pub-id></element-citation></ref><ref id="ref44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brody</surname><given-names>JM</given-names></name><name><surname>Butrus</surname><given-names>SI</given-names></name><name><surname>Laby</surname><given-names>DM</given-names></name><name><surname>Ashraf</surname><given-names>MF</given-names></name><name><surname>Rabinowitz</surname><given-names>AI</given-names></name><name><surname>Parenti</surname><given-names>DM</given-names></name></person-group><article-title>Anterior segment findings in AIDS patients withcytomegalovirus retinitis</article-title><source>Graefes Arch Clin Exp Ophthalmol</source><year>1995</year><volume>233</volume><fpage>374</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">7672626</pub-id></element-citation></ref><ref id="ref45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chee</surname><given-names>SP</given-names></name><name><surname>Bacsal</surname><given-names>K</given-names></name><name><surname>Jap</surname><given-names>A</given-names></name><name><surname>Se-Thoe</surname><given-names>SY</given-names></name><name><surname>Cheng</surname><given-names>CL</given-names></name><name><surname>Tan</surname><given-names>BH</given-names></name></person-group><article-title>Cornealendotheliitis associated with evidence of cytomegalovirusinfection</article-title><year>2007</year><volume>114</volume><fpage>798</fpage><lpage>803</lpage></element-citation></ref><ref id="ref46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koizumi</surname><given-names>N</given-names></name><name><surname>Yamasaki</surname><given-names>K</given-names></name><name><surname>Kawasaki</surname><given-names>S</given-names></name><name><surname>Sotozono</surname><given-names>C</given-names></name><name><surname>Inatomi</surname><given-names>T</given-names></name><name><surname>Mochida</surname><given-names>C</given-names></name><etal/></person-group><article-title>Cytomegalovirus in aqueous humor from an eyewith corneal endotheliitis</article-title><source>Am J Ophthalmol</source><year>2006</year><volume>141</volume><fpage>564</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">16490509</pub-id></element-citation></ref><ref id="ref47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Markomichelakis</surname><given-names>NN</given-names></name><name><surname>Canakis</surname><given-names>C</given-names></name><name><surname>Zafirakis</surname><given-names>P</given-names></name><name><surname>Marakis</surname><given-names>T</given-names></name><name><surname>Mallias</surname><given-names>I</given-names></name><name><surname>Theodossiadis</surname><given-names>G</given-names></name></person-group><article-title>Cytomegalovirus as a cause of anterior uveitiswith sectoral iris atrophy</article-title><source>Ophthalmology</source><year>2002</year><volume>109</volume><fpage>879</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">11986091</pub-id></element-citation></ref><ref id="ref48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Boxtel</surname><given-names>LA</given-names></name><name><surname>van der Lelij</surname><given-names>A</given-names></name><name><surname>van der Meer</surname><given-names>J</given-names></name><name><surname>Los</surname><given-names>LI</given-names></name></person-group><article-title>Cytomegalovirus as a cause of anterior uveitis in immunocompetentpatients</article-title><source>Ophthalmology</source><year>2007</year><volume>114</volume><fpage>1358</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">17296229</pub-id></element-citation></ref><ref id="ref49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fillet</surname><given-names>AM</given-names></name></person-group><article-title>Prophylaxis of herpesvirus infections inimmunocompetent and immunocompromised older patients</article-title><source>Drugs Aging</source><year>2002</year><volume>19</volume><fpage>343</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">12093321</pub-id></element-citation></ref><ref id="ref50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rottinghaus</surname><given-names>ST</given-names></name><name><surname>Whitley</surname><given-names>RJ</given-names></name></person-group><article-title>Current non-AIDS antiviralchemotherapy</article-title><source>Exp Rev Anti Infect Ther</source><year>2007</year><volume>5</volume><fpage>217</fpage><lpage>30</lpage></element-citation></ref><ref id="ref51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pannell</surname><given-names>RS</given-names></name><name><surname>Fleming</surname><given-names>DM</given-names></name><name><surname>Cross</surname><given-names>KW</given-names></name></person-group><article-title>The incidence of molluscumcontagiosum, scabies and lichen planus</article-title><source>Epidemiol Infect</source><year>2005</year><volume>133</volume><fpage>985</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">16274495</pub-id></element-citation></ref><ref id="ref52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leahey</surname><given-names>AB</given-names></name><name><surname>Shane</surname><given-names>JJ</given-names></name><name><surname>Listhaus</surname><given-names>A</given-names></name><name><surname>Trachtman</surname><given-names>M</given-names></name></person-group><article-title>Molluscumcontagiosum eyelid lesions as the initial manifestation of acquiredimmunodeficiency syndrome</article-title><source>Am J Ophthalmol</source><year>1997</year><volume>124</volume><fpage>240</fpage><lpage>1</lpage><pub-id pub-id-type="pmid">9262550</pub-id></element-citation></ref><ref id="ref53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biswas</surname><given-names>J</given-names></name><name><surname>Therese</surname><given-names>L</given-names></name><name><surname>Kumarasamy</surname><given-names>N</given-names></name><name><surname>Solomon</surname><given-names>S</given-names></name><name><surname>Yesudian</surname><given-names>P</given-names></name></person-group><article-title>Lidabscess with extensive molluscum contagiosum in a patient withacquired immunodeficiency syndrome</article-title><source>Indian J Ophthalmol</source><year>1997</year><volume>45</volume><fpage>234</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">9567020</pub-id></element-citation></ref><ref id="ref54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ratnam</surname><given-names>I</given-names></name><name><surname>Chiu</surname><given-names>C</given-names></name><name><surname>Kandala</surname><given-names>NB</given-names></name><name><surname>Easterbrook</surname><given-names>PJ</given-names></name></person-group><article-title>Incidence andrisk factors for immune reconstitution inflammatory syndrome inan ethnically diverse HIV type 1-infected cohort</article-title><source>Clin Infect Dis</source><year>2006</year><volume>42</volume><fpage>418</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">16392092</pub-id></element-citation></ref><ref id="ref55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moraes</surname><given-names>HV</given-names><suffix>Jr</suffix></name></person-group><article-title>Ocular manifestations of HIV-AIDS</article-title><source>Curr Opin Ophthalmol</source><year>2002</year><volume>13</volume><fpage>397</fpage><lpage>403</lpage><pub-id pub-id-type="pmid">12441844</pub-id></element-citation></ref><ref id="ref56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aristimuno</surname><given-names>B</given-names></name><name><surname>Nirankari</surname><given-names>VS</given-names></name><name><surname>Hemady</surname><given-names>RK</given-names></name><name><surname>Rodrigues</surname><given-names>MM</given-names></name></person-group><article-title>Spontaneous ulcerative keratitis in immunocompromised patients</article-title><source>Am J Ophthalmol</source><year>1993</year><volume>115</volume><fpage>202</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">8430729</pub-id></element-citation></ref><ref id="ref57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>B</given-names></name><name><surname>Kronborg</surname><given-names>G</given-names></name></person-group><article-title>Acanthamoeba keratitis in a non-contactlens wearer with human immunodeficiency virus</article-title><source>Scand J Infect Dis</source><year>2003</year><volume>35</volume><fpage>207</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">12751722</pub-id></element-citation></ref><ref id="ref58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tandon</surname><given-names>R</given-names></name><name><surname>Vajpayee</surname><given-names>RB</given-names></name><name><surname>Gupta</surname><given-names>V</given-names></name><name><surname>Vajpayee</surname><given-names>M</given-names></name><name><surname>Satpathy</surname><given-names>G</given-names></name><name><surname>Dada</surname><given-names>T</given-names></name></person-group><article-title>Polymicrobial keratitis in an HIV-positive patient</article-title><source>Indian J Ophthalmol</source><year>2003</year><volume>51</volume><fpage>87</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">12701872</pub-id></element-citation></ref><ref id="ref59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nanda</surname><given-names>M</given-names></name><name><surname>Pflugfelder</surname><given-names>SC</given-names></name><name><surname>Holland</surname><given-names>S</given-names></name></person-group><article-title>Fulminant pseudomonalkeratitis and scleritis in human immunodeficiency virus-infectedpatients</article-title><source>Arch Ophthalmol</source><year>1991</year><volume>109</volume><fpage>503</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">2012549</pub-id></element-citation></ref><ref id="ref60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>RK</given-names></name><name><surname>Goh</surname><given-names>BT</given-names></name><name><surname>Estreich</surname><given-names>S</given-names></name><name><surname>Cox</surname><given-names>SN</given-names></name><name><surname>Levy</surname><given-names>I</given-names></name></person-group><article-title>Adult gonococcalkeratoconjunctivitis with AIDS</article-title><source>Br J Ophthalmol</source><year>1990</year><volume>74</volume><fpage>52</fpage><pub-id pub-id-type="pmid">2306446</pub-id></element-citation></ref><ref id="ref61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bryan</surname><given-names>RT</given-names></name></person-group><article-title>Microsporidiosis as an AIDS-related opportunisticinfection</article-title><source>Clin Infect Dis</source><year>1995</year><volume>21</volume><fpage>S62</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">8547514</pub-id></element-citation></ref><ref id="ref62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedberg</surname><given-names>DN</given-names></name><name><surname>Stenson</surname><given-names>SM</given-names></name><name><surname>Orenstein</surname><given-names>JM</given-names></name><name><surname>Tierno</surname><given-names>PM</given-names></name><name><surname>Charles</surname><given-names>NC</given-names></name></person-group><article-title>Microsporidial keratoconjunctivitis in acquired immunodeficiencysyndrome</article-title><source>Arch Ophthalmol</source><year>1990</year><volume>108</volume><fpage>504</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">2108656</pub-id></element-citation></ref><ref id="ref63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lowder</surname><given-names>CY</given-names></name><name><surname>McMahon</surname><given-names>JT</given-names></name><name><surname>Meisler</surname><given-names>DM</given-names></name><name><surname>Dodds</surname><given-names>EM</given-names></name><name><surname>Calabrese</surname><given-names>LH</given-names></name><name><surname>Didier</surname><given-names>ES</given-names></name><etal/></person-group><article-title>Microsporidial keratoconjunctivitis caused byseptata intestinalis in a patient with acquired immunodeficiencysyndrome</article-title><source>Am J Ophthalmol</source><year>1996</year><volume>121</volume><fpage>715</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">8644819</pub-id></element-citation></ref><ref id="ref64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carr</surname><given-names>A</given-names></name><name><surname>Marriott</surname><given-names>D</given-names></name><name><surname>Field</surname><given-names>A</given-names></name><name><surname>Vasak</surname><given-names>E</given-names></name><name><surname>Cooper</surname><given-names>DA</given-names></name></person-group><article-title>Treatment ofHIV-1-associated microsporidiosis and cryptosporidiosis withcombination antiretroviral therapy</article-title><source>Lancet</source><year>1998</year><volume>351</volume><fpage>256</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">9457096</pub-id></element-citation></ref><ref id="ref65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martins</surname><given-names>SA</given-names></name><name><surname>Muccioli</surname><given-names>C</given-names></name><name><surname>Belfort</surname><given-names>R</given-names><suffix>Jr</suffix></name><name><surname>Castelo</surname><given-names>A</given-names></name></person-group><article-title>Resolution ofmicrosporidial keratoconjunctivitis in an AIDS patient treated withhighly active antiretroviral therapy</article-title><source>Am J Ophthalmol</source><year>2001</year><volume>131</volume><fpage>378</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11239874</pub-id></element-citation></ref><ref id="ref66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gajdatsy</surname><given-names>AD</given-names></name><name><surname>Tay-Kearney</surname><given-names>ML</given-names></name></person-group><article-title>Microsporidial keratoconjunctivitisafter HAART</article-title><source>Clin Exp Ophthalmol</source><year>2001</year><volume>29</volume><fpage>327</fpage><lpage>9</lpage></element-citation></ref><ref id="ref67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benson</surname><given-names>CA</given-names></name><name><surname>Kaplan</surname><given-names>JE</given-names></name><name><surname>Masur</surname><given-names>H</given-names></name><name><surname>Pau</surname><given-names>A</given-names></name><name><surname>Holmes</surname><given-names>KK</given-names></name><name><surname>CDC</surname></name></person-group><article-title>Treating opportunistic infections among HIV-infected adults andadolescents: Recommendations from CDC, the National Institutesof Health, and the HIV Medicine Association</article-title><source>MMWR Recomm Rep</source><year>2004</year><volume>53</volume><fpage>1</fpage><lpage>112</lpage><pub-id pub-id-type="pmid">15841069</pub-id></element-citation></ref><ref id="ref68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cano-Parra</surname><given-names>JL</given-names></name><name><surname>Diaz-LLopis</surname><given-names>ML</given-names></name><name><surname>Cordoba</surname><given-names>JL</given-names></name><name><surname>Gobernado</surname><given-names>ML</given-names></name><name><surname>Navea</surname><given-names>AL</given-names></name><name><surname>Menezo</surname><given-names>JL</given-names></name></person-group><article-title>Acute iridocyclitis in a patient with AIDSdiagnosed as toxoplasmosis by PCR</article-title><source>Ocul Immunol Inflamm</source><year>2000</year><volume>8</volume><fpage>127</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">10980687</pub-id></element-citation></ref><ref id="ref69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Helm</surname><given-names>CJ</given-names></name><name><surname>Holland</surname><given-names>GN</given-names></name></person-group><article-title>Ocular tuberculosis</article-title><source>Surv Ophthalmol</source><year>1993</year><volume>38</volume><fpage>229</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">8310395</pub-id></element-citation></ref><ref id="ref70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Babu</surname><given-names>RB</given-names></name><name><surname>Sudharshan</surname><given-names>S</given-names></name><name><surname>Kumarasamy</surname><given-names>N</given-names></name><name><surname>Therese</surname><given-names>KL</given-names></name><name><surname>Biswas</surname><given-names>J</given-names></name></person-group><article-title>Ocular tuberculosis in acquired immunodeficiency syndrome</article-title><source>Am J Ophthalmol</source><year>2006</year><volume>142</volume><fpage>413</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16935585</pub-id></element-citation></ref><ref id="ref71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouza</surname><given-names>E</given-names></name><name><surname>Merino</surname><given-names>P</given-names></name><name><surname>Munoz</surname><given-names>P</given-names></name><name><surname>Sanchez-Carrillo</surname><given-names>C</given-names></name><name><surname>Y&#x000e1;&#x000f1;ez</surname><given-names>J</given-names></name><name><surname>Cort&#x000e9;s</surname><given-names>C</given-names></name></person-group><article-title>Ocular tuberculosis: A prospective study in a general hospital</article-title><source>Medicine (Baltimore)</source><year>1997</year><volume>76</volume><fpage>53</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">9064488</pub-id></element-citation></ref><ref id="ref72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>JI</given-names></name><name><surname>Saragas</surname><given-names>SJ</given-names></name></person-group><article-title>Endophthalmitis due to Mycobacteriumavium in a patient with AIDS</article-title><source>Ann Ophthalmol</source><year>1990</year><volume>22</volume><fpage>47</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">2316950</pub-id></element-citation></ref><ref id="ref73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gopal</surname><given-names>L</given-names></name><name><surname>Rao</surname><given-names>SK</given-names></name><name><surname>Biswas</surname><given-names>J</given-names></name><name><surname>Madhavan</surname><given-names>HN</given-names></name><name><surname>Agarwal</surname><given-names>S</given-names></name></person-group><article-title>Tuberculousgranuloma managed by full thickness eye wall resection</article-title><source>Am J Ophthalmol</source><year>2003</year><volume>135</volume><fpage>93</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">12504705</pub-id></element-citation></ref><ref id="ref74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valentina</surname><given-names>C</given-names></name><name><surname>Mircla</surname><given-names>C</given-names></name></person-group><article-title>Phlyctenular keratoconjunctivitis and lymphnode tuberculosis</article-title><source>Ophthalmologia</source><year>1999</year><volume>48</volume><fpage>15</fpage><lpage>8</lpage></element-citation></ref><ref id="ref75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jennings</surname><given-names>A</given-names></name><name><surname>Bilous</surname><given-names>M</given-names></name><name><surname>Asimakis</surname><given-names>P</given-names></name><name><surname>Maloof</surname><given-names>AJ</given-names></name></person-group><article-title>Mycobacteriumtuberculosis presenting as chronic red eye</article-title><source>Cornea</source><year>2006</year><volume>25</volume><fpage>1118</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">17133069</pub-id></element-citation></ref><ref id="ref76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singal</surname><given-names>A</given-names></name><name><surname>Aggarwal</surname><given-names>P</given-names></name><name><surname>Pandhi</surname><given-names>D</given-names></name><name><surname>Rohatgi</surname><given-names>J</given-names></name></person-group><article-title>Cutaneous tuberculosisand phlyctenular keratoconjunctivitis: A forgotten association</article-title><source>Indian J Dermatol Venereol Leprol</source><year>2006</year><volume>72</volume><fpage>290</fpage><lpage>2</lpage><pub-id pub-id-type="pmid">16880576</pub-id></element-citation></ref><ref id="ref77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dinning</surname><given-names>WJ</given-names></name><name><surname>Marston</surname><given-names>S</given-names></name></person-group><article-title>Cutaneous and ocular tuberculosis:A review</article-title><source>J Royal Soc Med</source><year>1985</year><volume>78</volume><fpage>576</fpage><lpage>81</lpage></element-citation></ref><ref id="ref78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muccioli</surname><given-names>C</given-names></name><name><surname>Belfort Junior</surname><given-names>R</given-names></name><name><surname>Neves</surname><given-names>R</given-names></name><name><surname>Rao</surname><given-names>N</given-names></name></person-group><article-title>Limbal and choroidalCryptococcus infection in the acquired immunodeficiencysyndrome</article-title><source>Am J Ophthalmol</source><year>1995</year><volume>120</volume><fpage>539</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">7573321</pub-id></element-citation></ref><ref id="ref79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garelick</surname><given-names>JM</given-names></name><name><surname>Khodabakhsh</surname><given-names>AJ</given-names></name><name><surname>Lopez</surname><given-names>Y</given-names></name><name><surname>Bamji</surname><given-names>M</given-names></name><name><surname>Lister</surname><given-names>M</given-names></name></person-group><article-title>Scleralulceration caused by cryptococcus albidus in a patient withacquired immune deficiency syndrome</article-title><source>Cornea</source><year>2004</year><volume>23</volume><fpage>730</fpage><lpage>1</lpage><pub-id pub-id-type="pmid">15448503</pub-id></element-citation></ref><ref id="ref80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Acharya</surname><given-names>NR</given-names></name><name><surname>Cunningham</surname><given-names>ET</given-names><suffix>Jr</suffix></name></person-group><article-title>Corneal, anterior segment, andadnexal manifestations of human immunodeficiency virus</article-title><source>Int Ophthalmol Clin</source><year>1998</year><volume>38</volume><fpage>161</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">10081732</pub-id></element-citation></ref><ref id="ref81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLeish</surname><given-names>WM</given-names></name><name><surname>Pulido</surname><given-names>JS</given-names></name><name><surname>Holland</surname><given-names>S</given-names></name><name><surname>Culbertson</surname><given-names>WW</given-names></name><name><surname>Winward</surname><given-names>K</given-names></name></person-group><article-title>The ocular manifestations of syphilis in the human immunodeficiencyvirus type 1-infected host</article-title><source>Ophthalmology</source><year>1990</year><volume>97</volume><fpage>196</fpage><lpage>203</lpage><pub-id pub-id-type="pmid">2326008</pub-id></element-citation></ref><ref id="ref82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becerra</surname><given-names>LI</given-names></name><name><surname>Ksiazek</surname><given-names>SM</given-names></name><name><surname>Savino</surname><given-names>PJ</given-names></name><name><surname>Marcus</surname><given-names>DK</given-names></name><name><surname>Buckley</surname><given-names>RM</given-names></name><name><surname>Sergott</surname><given-names>RC</given-names></name><etal/></person-group><article-title>Syphilitic uveitis in human immunodeficiencyvirus-infected and non infected patients</article-title><source>Ophthalmology</source><year>1989</year><volume>96</volume><fpage>1727</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">2622618</pub-id></element-citation></ref><ref id="ref83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Musher</surname><given-names>DM</given-names></name><name><surname>Hamill</surname><given-names>RJ</given-names></name><name><surname>Baughn</surname><given-names>RE</given-names></name></person-group><article-title>Effect of human immunodeficiencyvirus (HIV) infection on the course of syphilis and on the responseto treatment</article-title><source>Ann Intern Med</source><year>1990</year><volume>113</volume><fpage>872</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">2240901</pub-id></element-citation></ref><ref id="ref84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aldave</surname><given-names>AJ</given-names></name><name><surname>King</surname><given-names>JA</given-names></name><name><surname>Cunningham</surname><given-names>ET</given-names><suffix>Jr</suffix></name></person-group><article-title>Ocular syphilis</article-title><source>Curr Opin Ophthalmol</source><year>2001</year><volume>12</volume><fpage>433</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">11734683</pub-id></element-citation></ref><ref id="ref85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>CS</given-names></name><name><surname>Klausner</surname><given-names>JD</given-names></name><name><surname>Bolan</surname><given-names>GA</given-names></name></person-group><article-title>Managing syphilis in the HIV-infected patient</article-title><source>Curr Infect Dis Rep</source><year>2004</year><volume>6</volume><fpage>72</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">14733852</pub-id></element-citation></ref><ref id="ref86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moloney</surname><given-names>G</given-names></name><name><surname>Branley</surname><given-names>M</given-names></name><name><surname>Kotsiou</surname><given-names>G</given-names></name><name><surname>Rhodes</surname><given-names>D</given-names></name></person-group><article-title>Syphilis presenting asscleritis in an HIV-positive man undergoing immune reconstitution</article-title><source>Clin Experiment Ophthalmol</source><year>2004</year><volume>32</volume><fpage>526</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">15498066</pub-id></element-citation></ref><ref id="ref87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>CS</given-names></name><name><surname>Klausner</surname><given-names>JD</given-names></name><name><surname>Bolan</surname><given-names>GA</given-names></name></person-group><article-title>Managing syphilis in the HIV-infected patient</article-title><source>Curr Infect Dis Rep</source><year>2004</year><volume>6</volume><fpage>72</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">14733852</pub-id></element-citation></ref><ref id="ref88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosberger</surname><given-names>DF</given-names></name><name><surname>Heinemann</surname><given-names>MH</given-names></name><name><surname>Friedberg</surname><given-names>DN</given-names></name><name><surname>Holland</surname><given-names>GN</given-names></name></person-group><article-title>Uveitisassociated with human immunodeficiency virus infection</article-title><source>Am J Ophthalmol</source><year>1998</year><volume>125</volume><fpage>301</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">9512146</pub-id></element-citation></ref><ref id="ref89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doris</surname><given-names>JP</given-names></name><name><surname>Saha</surname><given-names>K</given-names></name><name><surname>Jones</surname><given-names>NP</given-names></name><name><surname>Sukthankar</surname><given-names>A</given-names></name></person-group><article-title>Ocular syphilis: The new epidemic</article-title><source>Eye</source><year>2006</year><volume>20</volume><fpage>703</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">15933744</pub-id></element-citation></ref><ref id="ref90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levinson</surname><given-names>RD</given-names></name><name><surname>Vann</surname><given-names>R</given-names></name><name><surname>Davis</surname><given-names>JL</given-names></name><name><surname>Friedberg</surname><given-names>DN</given-names></name><name><surname>Tufail</surname><given-names>A</given-names></name><name><surname>Terry</surname><given-names>BT</given-names></name><etal/></person-group><article-title>Chronic multifocal retinal infiltrates in patients infected withhuman immunodeficiency virus</article-title><source>Am J Ophthalmol</source><year>1998</year><volume>125</volume><fpage>312</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">9512148</pub-id></element-citation></ref><ref id="ref91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tschachler</surname><given-names>E</given-names></name><name><surname>Bergstresser</surname><given-names>PR</given-names></name><name><surname>Stingl</surname><given-names>G</given-names></name></person-group><article-title>HIV-related skin diseases</article-title><source>Lancet</source><year>1996</year><volume>348</volume><fpage>659</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">8782758</pub-id></element-citation></ref><ref id="ref92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biswas</surname><given-names>J</given-names></name><name><surname>Madhavan</surname><given-names>HN</given-names></name><name><surname>Kumarasamy</surname><given-names>N</given-names></name><name><surname>Solomon</surname><given-names>S</given-names></name></person-group><article-title>Blepharitis and lid ulcer as initial ocular manifestations inacquired immunodeficiency syndrome (AIDS) patients</article-title><source>Indian J Ophthalmol</source><year>1997</year><volume>45</volume><fpage>233</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">9567019</pub-id></element-citation></ref><ref id="ref93"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmid</surname><given-names>K</given-names></name><name><surname>Wild</surname><given-names>T</given-names></name><name><surname>Bolz</surname><given-names>M</given-names></name><name><surname>Horvat</surname><given-names>R</given-names></name><name><surname>Jurecka</surname><given-names>W</given-names></name><name><surname>Zehetmayer</surname><given-names>M</given-names></name></person-group><article-title>Kaposi&#x02032;s sarcoma of the conjunctiva leads to a diagnosis ofacquired immunodeficiency syndrome</article-title><source>Acta Ophthalmol Scand</source><year>2003</year><volume>81</volume><fpage>411</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">12859274</pub-id></element-citation></ref><ref id="ref94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corti</surname><given-names>M</given-names></name><name><surname>Solari</surname><given-names>R</given-names></name><name><surname>de Carolis</surname><given-names>L</given-names></name><name><surname>Corraro</surname><given-names>R</given-names></name></person-group><article-title>Eye involvement inAIDS-related Kaposi sarcoma</article-title><source>Enferm Infect Microbiol Clin</source><year>2001</year><volume>19</volume><fpage>3</fpage><lpage>6</lpage></element-citation></ref><ref id="ref95"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rutgers</surname><given-names>JL</given-names></name><name><surname>Wieczorek</surname><given-names>R</given-names></name><name><surname>Bonetti</surname><given-names>F</given-names></name><name><surname>Kaplan</surname><given-names>KL</given-names></name><name><surname>Posnett</surname><given-names>DN</given-names></name><name><surname>Friedman-Kien</surname><given-names>AE</given-names></name><etal/></person-group><article-title>The expression of endothelial cellsurface antigens by AIDS-associated Kaposi&#x02032;s sarcoma: Evidencefor a vascular endothelial cell origin</article-title><source>Am J Pathol</source><year>1986</year><volume>122</volume><fpage>493</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">3953772</pub-id></element-citation></ref><ref id="ref96"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dugel</surname><given-names>PU</given-names></name><name><surname>Gill</surname><given-names>PS</given-names></name><name><surname>Frangieh</surname><given-names>GT</given-names></name><name><surname>Rao</surname><given-names>NA</given-names></name></person-group><article-title>Ocular adnexalKaposi&#x02032;s sarcoma in acquired immunodeficiency syndrome</article-title><source>Am J Ophthalmol</source><year>1990</year><volume>110</volume><fpage>500</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">2240135</pub-id></element-citation></ref><ref id="ref97"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dugel</surname><given-names>PU</given-names></name><name><surname>Gill</surname><given-names>PS</given-names></name><name><surname>Frangieh</surname><given-names>GT</given-names></name><name><surname>Rao</surname><given-names>NA</given-names></name></person-group><article-title>Treatment of ocularadnexal Kaposi&#x02032;s sarcoma in acquired immune deficiencysyndrome</article-title><source>Ophthalmology</source><year>1992</year><volume>99</volume><fpage>1127</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">1495793</pub-id></element-citation></ref><ref id="ref98"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheschonka</surname><given-names>A</given-names></name><name><surname>M&#x000f6;sch</surname><given-names>M</given-names></name><name><surname>Krieglsteiner</surname><given-names>S</given-names></name><name><surname>Turowski</surname><given-names>B</given-names></name><name><surname>Zanella</surname><given-names>FE</given-names></name></person-group><article-title>Pre- and post treatment MR imaging in AIDS-relatedKaposi sarcoma of the conjunctiva and lacrimal gland</article-title><source>AJNR Am J Neuroradiol</source><year>2003</year><volume>24</volume><fpage>1327</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">12917121</pub-id></element-citation></ref><ref id="ref99"><label>99</label><element-citation publication-type="journal"><collab>International Collaboration on HIV and Cancer</collab><article-title>Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infectedadults</article-title><source>J Natl Cancer Inst</source><year>2000</year><volume>92</volume><fpage>1823</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">11078759</pub-id></element-citation></ref><ref id="ref100"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crane</surname><given-names>HM</given-names></name><name><surname>Deubner</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>JC</given-names></name><name><surname>Swanson</surname><given-names>PE</given-names></name><name><surname>Harrington</surname><given-names>RD</given-names></name></person-group><article-title>Fatal Kaposi&#x02032;s sarcoma-associated immune reconstitutionfollowing HAART initiation</article-title><source>Int J STD AIDS</source><year>2005</year><volume>16</volume><fpage>80</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">15705280</pub-id></element-citation></ref><ref id="ref101"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Connick</surname><given-names>E</given-names></name><name><surname>Kane</surname><given-names>MA</given-names></name><name><surname>White</surname><given-names>IE</given-names></name><name><surname>Ryder</surname><given-names>J</given-names></name><name><surname>Campbell</surname><given-names>TB</given-names></name></person-group><article-title>Immunereconstitution inflammatory syndrome associated with kaposisarcoma during potent antiretroviral therapy</article-title><source>Clin Infect Dis</source><year>2004</year><volume>39</volume><fpage>1852</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">15578411</pub-id></element-citation></ref><ref id="ref102"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muccioli</surname><given-names>C</given-names></name><name><surname>Belfort</surname><given-names>R</given-names></name><name><surname>Burnier</surname><given-names>M</given-names></name><name><surname>Rao</surname><given-names>N</given-names></name></person-group><article-title>Squamous cell carcinomaof the conjunctiva in a patient with the acquired immunedeficiency syndrome</article-title><source>Am J Ophthalmol</source><year>1996</year><volume>121</volume><fpage>94</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">8554088</pub-id></element-citation></ref><ref id="ref103"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fogla</surname><given-names>R</given-names></name><name><surname>Biswas</surname><given-names>J</given-names></name><name><surname>Krishnakumar</surname><given-names>S</given-names></name><name><surname>Madhavan</surname><given-names>HN</given-names></name><name><surname>Kumarasamy</surname><given-names>N</given-names></name><name><surname>Solomon</surname><given-names>S</given-names></name></person-group><article-title>Squamous cell carcinoma of the conjunctiva as initialpresenting sign in a patient with acquired immunodeficiencysyndrome (AIDS) due to human immunodeficiency virus type-2</article-title><source>Eye</source><year>2000</year><volume>14</volume><fpage>246</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">10845028</pub-id></element-citation></ref><ref id="ref104"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Porges</surname><given-names>Y</given-names></name><name><surname>Groisman</surname><given-names>GM</given-names></name></person-group><article-title>Prevalence of HIV with conjunctivalsquamous cell neoplasia in an African provincial hospital</article-title><source>Cornea</source><year>2003</year><volume>22</volume><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">12502938</pub-id></element-citation></ref><ref id="ref105"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holkar</surname><given-names>S</given-names></name><name><surname>Mudhar</surname><given-names>HS</given-names></name><name><surname>Jain</surname><given-names>A</given-names></name><name><surname>Gupta</surname><given-names>M</given-names></name><name><surname>Rogstad</surname><given-names>KE</given-names></name><name><surname>Parsons</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Regression of invasive conjunctival Squamous carcinoma inan HIV-positive patient on antiretroviral therapy</article-title><source>Int J STD AIDS</source><year>2005</year><volume>16</volume><fpage>782</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">16336757</pub-id></element-citation></ref><ref id="ref106"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandler</surname><given-names>AS</given-names></name><name><surname>Kaplan</surname><given-names>L</given-names></name></person-group><article-title>AIDS lymphoma</article-title><source>Curr Opin Oncol</source><year>1996</year><volume>8</volume><fpage>377</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">8914804</pub-id></element-citation></ref><ref id="ref107"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Espana-Gregori</surname><given-names>E</given-names></name><name><surname>Hernandez</surname><given-names>M</given-names></name><name><surname>Menezo-Rozalen</surname><given-names>JL</given-names></name><name><surname>Diaz-Llopis</surname><given-names>M</given-names></name></person-group><article-title>Metastatic anterior chamber non-Hodgkin lymphomain a patient with acquired immunodeficiency syndrome</article-title><source>Am J Ophthalmol</source><year>1997</year><volume>124</volume><fpage>243</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">9262552</pub-id></element-citation></ref><ref id="ref108"><label>108</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rivero</surname><given-names>ME</given-names></name><name><surname>Kuppermann</surname><given-names>BD</given-names></name><name><surname>Wiley</surname><given-names>CA</given-names></name><name><surname>Garcia</surname><given-names>CR</given-names></name><name><surname>Smith</surname><given-names>MD</given-names></name><name><surname>Dreilinger</surname><given-names>A</given-names></name><etal/></person-group><article-title>Acquired immunodeficiency syndrome-relatedintraocular B-cell lymphoma</article-title><source>Arch Ophthalmol</source><year>1999</year><volume>117</volume><fpage>616</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">10326958</pub-id></element-citation></ref><ref id="ref109"><label>109</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldberg</surname><given-names>SH</given-names></name><name><surname>Fieo</surname><given-names>AG</given-names></name><name><surname>Wolz</surname><given-names>DE</given-names></name></person-group><article-title>Primary eyelid non- Hodgkin&#x02032;slymphoma in a patient with acquired immunodeficiencysyndrome</article-title><source>Am J Ophthalmol</source><year>1992</year><volume>113</volume><fpage>216</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">1550198</pub-id></element-citation></ref><ref id="ref110"><label>110</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matzkin</surname><given-names>DC</given-names></name><name><surname>Slamovits</surname><given-names>TL</given-names></name><name><surname>Rosenbaum</surname><given-names>PS</given-names></name></person-group><article-title>Simultaneousintraocular and orbital non-Hodgkin lymphoma in the acquiredimmune deficiency syndrome</article-title><source>Ophthalmology</source><year>1994</year><volume>101</volume><fpage>850</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">8190470</pub-id></element-citation></ref><ref id="ref111"><label>111</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Batard</surname><given-names>ML</given-names></name><name><surname>Cheret</surname><given-names>A</given-names></name><name><surname>Muller</surname><given-names>P</given-names></name><name><surname>Sarrouy</surname><given-names>J</given-names></name><name><surname>Mareel</surname><given-names>A</given-names></name><name><surname>Lamaury</surname><given-names>I</given-names></name></person-group><article-title>Bacillary angiomatosis associated with AIDS</article-title><source>Ann Dermatol Venereol</source><year>2006</year><volume>133</volume><fpage>498</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">16760847</pub-id></element-citation></ref><ref id="ref112"><label>112</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ormerod</surname><given-names>LD</given-names></name><name><surname>Dailey</surname><given-names>JP</given-names></name></person-group><article-title>Ocular manifestations of cat-scratchdisease</article-title><source>Curr Opin Ophthalmol</source><year>1999</year><volume>10</volume><fpage>209</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">10537781</pub-id></element-citation></ref><ref id="ref113"><label>113</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matui</surname><given-names>R</given-names></name><name><surname>Nussenblatt</surname><given-names>R</given-names></name><name><surname>de Smet</surname><given-names>MD</given-names></name></person-group><article-title>Prevalance of tearhyposecretion and vitamin A deficiency in patients with AIDS</article-title><source>Invest Ophthalmol Vis Sci</source><year>1994</year><volume>35</volume><fpage>1308</fpage></element-citation></ref><ref id="ref114"><label>114</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moraes</surname><given-names>HV</given-names><suffix>Jr</suffix></name></person-group><article-title>Ocular manifestations of HIV-AIDS</article-title><source>Curr Opin Ophthalmol</source><year>2002</year><volume>13</volume><fpage>397</fpage><lpage>403</lpage><pub-id pub-id-type="pmid">12441844</pub-id></element-citation></ref><ref id="ref115"><label>115</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akpek</surname><given-names>EK</given-names></name><name><surname>Haddad</surname><given-names>RS</given-names></name><name><surname>Winkelstein</surname><given-names>JA</given-names></name><name><surname>Gottsch</surname><given-names>JD</given-names></name></person-group><article-title>Bilateralconsecutive central corneal perforations associated withhypogammaglobulinemia</article-title><source>Ophthalmology</source><year>2000</year><volume>107</volume><fpage>123</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">10647730</pub-id></element-citation></ref><ref id="ref116"><label>116</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raina</surname><given-names>UK</given-names></name><name><surname>Sharma</surname><given-names>V</given-names></name><name><surname>Jain</surname><given-names>S</given-names></name><name><surname>Arora</surname><given-names>R</given-names></name><name><surname>Mehta</surname><given-names>DK</given-names></name></person-group><article-title>Peripheral cornealthinning and silent corneal perforation in an HIV seropositivecase</article-title><source>Acta Ophthalmol Scand</source><year>2004</year><volume>82</volume><fpage>246</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">15043556</pub-id></element-citation></ref><ref id="ref117"><label>117</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>DA</given-names></name><name><surname>Sires</surname><given-names>BS</given-names></name></person-group><article-title>Acquired trichomegaly associated withacquired immunodeficiency syndrome</article-title><source>Arch Ophthalmol</source><year>1997</year><volume>115</volume><fpage>557</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9109774</pub-id></element-citation></ref><ref id="ref118"><label>118</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nash</surname><given-names>RW</given-names></name><name><surname>Lindquist</surname><given-names>TD</given-names></name></person-group><article-title>Bilateral angle-closure glaucoma associated with uveal effusion: Presenting sign of HIV infection</article-title><source>Surv Ophthalmol</source><year>1992</year><volume>36</volume><fpage>255</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">1549809</pub-id></element-citation></ref><ref id="ref119"><label>119</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lozano</surname><given-names>F</given-names></name><name><surname>Leon</surname><given-names>EM</given-names></name><name><surname>Mira</surname><given-names>JA</given-names></name><name><surname>Corzo</surname><given-names>JE</given-names></name><name><surname>G&#x000f3;mez-Mateos</surname><given-names>JM</given-names></name></person-group><article-title>Relapsing blepharitis in patients under highly active antiretroviraltherapy including indinavir</article-title><source>AIDS</source><year>2004</year><volume>18</volume><fpage>354</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">15075566</pub-id></element-citation></ref><ref id="ref120"><label>120</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>MR</given-names></name><name><surname>Reed</surname><given-names>G</given-names></name><name><surname>Csaky</surname><given-names>KG</given-names></name><name><surname>Polis</surname><given-names>MA</given-names></name><name><surname>Whitcup</surname><given-names>SM</given-names></name></person-group><article-title>Immune recovery uveitis in patients with cytomegalovirusretinitis taking highly active anti retroviral therapy</article-title><source>Am J Ophthalmol</source><year>2000</year><volume>130</volume><fpage>49</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">11004259</pub-id></element-citation></ref><ref id="ref121"><label>121</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>QD</given-names></name><name><surname>Kempen</surname><given-names>JH</given-names></name><name><surname>Bolton</surname><given-names>SG</given-names></name><name><surname>Dunn</surname><given-names>JP</given-names></name><name><surname>Jabs</surname><given-names>DA</given-names></name></person-group><article-title>Immunerecovery uveitis in patients with AIDS and cytomegalovirusretinitis after highly active antiretroviral therapy</article-title><source>Am J Ophthalmol</source><year>2000</year><volume>129</volume><fpage>634</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10844056</pub-id></element-citation></ref><ref id="ref122"><label>122</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karavellas</surname><given-names>MP</given-names></name><name><surname>Azen</surname><given-names>SP</given-names></name><name><surname>Macdonald</surname><given-names>JC</given-names></name><name><surname>Shufelt</surname><given-names>CL</given-names></name><name><surname>Lowder</surname><given-names>CY</given-names></name><name><surname>Plummer</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Immune recovery vitritis and uveitis in AIDS:Clinical predictors, sequelae and treatment outcomes</article-title><source>Retina</source><year>2001</year><volume>21</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11217922</pub-id></element-citation></ref><ref id="ref123"><label>123</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kempen</surname><given-names>JH</given-names></name><name><surname>Min</surname><given-names>YI</given-names></name><name><surname>Freeman</surname><given-names>WR</given-names></name><name><surname>Holland</surname><given-names>GN</given-names></name><name><surname>Friedberg</surname><given-names>DN</given-names></name><name><surname>Dieterich</surname><given-names>DT</given-names></name><etal/></person-group><article-title>Risk of immune recovery uveitis in patientswith AIDS and cytomegalovirus retinitis</article-title><source>Ophthalmology</source><year>2006</year><volume>113</volume><fpage>684</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">16581429</pub-id></element-citation></ref><ref id="ref124"><label>124</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tseng</surname><given-names>AL</given-names></name><name><surname>Walmsley</surname><given-names/></name></person-group><article-title>Rifabutin-associated uveitis</article-title><source>Ann Pharmacother</source><year>1995</year><volume>29</volume><fpage>1149</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">8573961</pub-id></element-citation></ref><ref id="ref125"><label>125</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>JL</given-names></name><name><surname>Taskintuna</surname><given-names>I</given-names></name><name><surname>Freeman</surname><given-names>WR</given-names></name><name><surname>Weinberg</surname><given-names>DV</given-names></name><name><surname>Feuer</surname><given-names>WJ</given-names></name><name><surname>Leonard</surname><given-names>RE</given-names></name></person-group><article-title>Iritis and hypotony after treatment with intravenouscidofovir for cytomegalovirus retinitis</article-title><source>Arch Ophthalmol</source><year>1997</year><volume>115</volume><fpage>733</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">9194724</pub-id></element-citation></ref><ref id="ref126"><label>126</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>AK</given-names></name><name><surname>Chronister</surname><given-names>CL</given-names></name></person-group><article-title>Sarcoidosis-related anterior uveitis in apatient with human immunodeficiency virus</article-title><source>J Am Optom Assoc</source><year>1999</year><volume>70</volume><fpage>384</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">10437340</pub-id></element-citation></ref><ref id="ref127"><label>127</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verma</surname><given-names>S</given-names></name><name><surname>Hughes</surname><given-names>JD</given-names></name><name><surname>Mabey</surname><given-names>D</given-names></name><name><surname>Graham</surname><given-names>EM</given-names></name></person-group><article-title>Symptomatic anterioruveitis in an HIV-positive patient</article-title><source>Int J STD AIDS</source><year>1999</year><volume>10</volume><fpage>268</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">12035782</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Figure 1</label><caption><p><italic>Herpes zoster</italic> ophthalmicus in a patient with AIDS</p></caption><alt-text>Figure 1</alt-text><graphic xlink:href="IndianJOphthalmol-56-363-g001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><p>Molluscum contagiosum in a child with AIDS</p></caption><alt-text>Figure 2</alt-text><graphic xlink:href="IndianJOphthalmol-56-363-g002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><p>Kaposi's sarcoma in a patient with AIDS</p></caption><alt-text>Figure 3</alt-text><graphic xlink:href="IndianJOphthalmol-56-363-g003"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><p>Squamous cell carcinoma as an initial manifestation ofAIDS</p></caption><alt-text>Figure 4</alt-text><graphic xlink:href="IndianJOphthalmol-56-363-g004"/></fig><fig id="F5" position="float"><label>Figure 5</label><caption><p>A patient of ulcerative blepharitis with AIDS</p></caption><alt-text>Figure 5</alt-text><graphic xlink:href="IndianJOphthalmol-56-363-g005"/></fig><fig id="F6" position="float"><label>Figure 6</label><caption><p>Severe anterior uveitis with hypopyon in case of immunerecovery uveitis with AIDS on protease inhibitor</p></caption><alt-text>Figure 6</alt-text><graphic xlink:href="IndianJOphthalmol-56-363-g006"/></fig></floats-group></article>